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ABSTRACT OF THE DISSERTATION
THIOREDOXIN AND JAB1 CONTROL ESTROGEN- AND ANTIESTROGENMEDIATED PROGRESSION OF THE CELL CYCLE THROUGH P27
INTERACTIONS
by
Rosalind Brigham Penney
Florida International University, 2011
Miami, Florida
Professor Deodutta Roy, Major Professor
A major problem with breast cancer treatment is the prevalence of antiestrogen
resistance, be it de novo or acquired after continued use. Many of the underlying
mechanisms of antiestrogen resistance are not clear, although estrogen receptor-mediated
actions have been identified as a pathway that is blocked by antiestrogens. Selective
estrogen receptor modulators (SERMs), such as tamoxifen, are capable of producing
reactive oxygen species (ROS) through metabolic activation, and these ROS, at high
levels, can induce irreversible growth arrest that is similar to the growth arrest incurred
by SERMs. This suggests that SERM-mediated growth arrest may also be through ROS
accumulation. Breast cancer receiving long-term antiestrogen treatment appears to adapt
to this increased, persistent level of ROS. This, in turn, leads to the disruption of
reversible redox signaling that involves redox-sensitive phosphatases and protein kinases
and transcription factors. This has downstream consequences for apoptosis, cell cycle
progression, and cell metabolism. For this dissertation, we explored if altering the ROS
formed by tamoxifen also alters sensitivity of the drug in resistant cells. We explored an
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association with a thioredoxin/Jab1/p27 pathway, and a possible role of dysregulation
of thioredoxin-mediated redox regulation contributing to the development of antiestrogen
resistance in breast cancer. We used standard laboratory techniques to perform proteomic
assays that showed cell proliferation, protein concentrations, redox states, and proteinprotein interactions. We found that increasing thioredoxin reductase levels, and thus
increasing the amount of reduced thioredoxin, increased tamoxifen sensitivity in
previously resistant cells, as well as altered estrogen and tamoxifen-induced ROS. We
also found that decreasing levels of Jab1 protein also increased tamoxifen sensitivity, and
that the downstream effects showed a decrease p27 phosphorylation in both cases. We
conclude that the chronic use of tamoxifen can lead to an increase in ROS that alters cell
signaling and causing cell growth in the presence of tamoxifen, and that this resistant cell
growth can be reversed with an alteration to the thioredoxin/Jab1 pathway.
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I.

INTRODUCTION

It is estimated that 1.2 million people will be diagnosed with breast cancer every year.
Through research on hormone replacement therapies and estrogen-receptor (ER)-based
therapies, estrogen has been found to be involved in the development of breast cancer.1
Currently, there are several options for the treatment of breast cancer, including surgery,
radiation, chemotherapy, and hormonal therapy. Antiestrogens (AEs) are a known
adjunctive therapy, and are used as a preventive measure as well. The most common form
of hormonal therapy has been, for many years, selective estrogen receptor modulators
(SERMs) such as tamoxifen, raloxifene, and toremifene.2

A major problem with the use of antiestrogens (AE) is the prevalence of resistance, either
at the outset of treatment or after continued use. The underlying mechanisms of
antiestrogen resistance remain unclear. ER-mediated actions were identified initially as a
pathway that was blocked in AE-treated cells, and inhibition of this pathway has been
shown to cause permanent growth arrest/cell death. Reactive oxygen species (ROS) are
an outcome of oxidative processes and can induce an irreversible growth arrest similar to
selective estrogen receptor modulator (SERM) antiestrogens. SERMs are capable of
producing ROS through their metabolic activation. These findings suggest that SERMs
may mediate growth arrest by a mechanism involving ROS accumulation.

The antioxidant thioredoxin may have a role in antiestrogen resistance in breast cancer.
As cells are chronically exposed to ROS from long-term tamoxifen treatment, they can
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adapt to this increasing level of ROS and oxidative stress. This can lead to oxidation of
certain cellular antioxidant systems, such as thioredoxin, causing them to become
inactive. The inactivation of the thioredoxin antioxidant family can then affect other
proteins such as PTPs or Jab1, or lead to the continued activation of cell signaling
pathways such as MAPKs (mitogen activating protein kinases), leading to the activation
of transcription factors such as AP-1 or NF-κB and subsequent cell proliferation.

We hypothesized that antiestrogen generated ROS, through the oxidization of Trx,
increases the amount of free Jab1 accessible to bind to p27. This, in turn, promotes the
loss of the inhibitory functions of p27, leading to antiestrogen resistance. Our goal, then,
was to investigate whether reducing oxidized Trx in antiestrogen-resistant breast cancer
cells restores the anti-proliferative function of antiestrogen treatments through restoring
the Trx to compete for Jab1 binding, and thus renewing the inhibitive quality of p27.

The following specific aims were set up to test the hypothesis:
Aim 1: To investigate whether reducing oxidized Trx restores the anti-proliferative action
of antiestrogen by: (i) determining if reducing Trx using ROS inhibitors and/or ROS
detoxifying enzymes and/or an overexpression of Trx reductase restores the antiproliferative effect of antiestrogens by increasing Trx binding with Jab-1 and renewing
the inhibitory function of p27; and (ii) investigating whether a persistent increase in
oxidative stress leads to antiestrogen resistance in previously sensitive breast cancer cells
through downregulating Trx reductase, upregulating Jab-1, and thus impairing the p27
inhibitory function.
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Aim 2: To determine the molecular mechanisms by which a pro-oxidative state may
promote the oxidation/inhibition of Trx, p27 inactivation by Jab-1, and cell cycle
progression by investigating whether redox signaling pathways in antiestrogen resistant
cells can either directly or indirectly regulate levels of oxidized Trx and p27 in
antiestrogen-resistant breast cancer cells.

Aim 3: Testing of the hypothesis using in vivo conditions by investigating whether ROS
inhibitors and/or Trx reductase can cooperate with antiestrogens to inhibit the
proliferation of estrogen-independent, antiestrogen-resistant breast cancer cells in a 3dimensional culture.

After beginning experiments, we chose to alter Aim 1 (ii) and not to perform Aim 3. We
wanted instead to explore the role of the protein tyrosine phosphatase PTEN in estrogenmediated oxidative stress in breast cancer cells, as PTP alteration may also occur due to
increased estrogen. We thought it important to explore the cell signaling pathways,
namely those associated with thioredoxin/Jab1 and p27, which occur due to estrogen
exposure in ER+ cells, as well as those initiated by the treatments. Both estrogen and
tamoxifen have been shown to increase levels of ROS in breast cancer cells,3 and thus our
findings may be applied to the formation of tamoxifen resistance through increased ROS.
Our specific aim was to show the alteration of ROS through the thioredoxin/Jab1
pathway and the effect on p27 phosphorylation in MCF-7 cells.
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II.

LITERATURE REVIEW:

THIOREDOXIN, CHANGES IN REDOX STATE OF CELLS AND A NEW
PERSPECTIVE IN AN UNDERSTANDING OF TAMOXIFEN RESISTANCE IN
BREAST CANCER TREATMENT

Abstract
A major problem with the use of antiestrogens (AE) is the prevalence of resistance, either
at the outset of treatment or after continued use. The underlying mechanisms of
AE resistance remain unclear. Estrogen receptor (ER)-mediated actions were identified
initially as a pathway that was blocked in AE-treated cells, and inhibition of this
pathway has been shown to cause permanent growth arrest/cell death. Reactive oxygen
species (ROS), a byproduct of oxidative processes, can induce an irreversible growth
arrest similar to selective estrogen receptor modulator (SERM) antiestrogens. SERMs are
capable of producing ROS through their metabolic activation. These findings suggest that
SERMs may mediate growth arrest by a mechanism involving ROS accumulation.

Breast cancer cells have higher amounts of ROS than normal cells, and chronic treatment
with tamoxifen or fulvestrant adds additional ROS. Breast cancer cells receiving longterm antiestrogen treatment appear to adapt to this increased, persistent level of ROS.
This, in turn, leads to the disruption of reversible redox signaling that involves redoxsensitive phosphatases and protein kinases such as ERK and AKT, and also
involves transcription factors such as AP-1 and NF-κB. This has downstream
consequences for apoptosis, cell cycle progression, and cell metabolism. This review
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discusses concepts in support of a possible role of dysregulation of thioredoxin-mediated
redox regulation contributing to the development of AE resistance in breast cancer. The
inactivation of the thioredoxin antioxidant family can disrupt reversible redox signaling
pathways and cause the cell to become unresponsive to AE-induced cell cycle arrest or
cell death, or lead to the continued activation of cell signaling pathways such as MAPKs,
leading to the activation of transcription factors and subsequent cell proliferation.

1. Introduction
Through research on hormone contraception, postmenopausal hormonal therapies and
estrogen-receptor (ER)-based endocrine therapies, we know that estrogen is a major risk
factor of breast cancer. 1, 4-14 Therefore, preventive strategies are predominantly restricted
to antiestrogenic (AE) stimulation of its cognate receptor. The ER-based endocrine
therapy includes selective estrogen receptor modulators (SERMs) (tamoxifen, raloxifene
[Evista], and toremifene [Fareston]), pure antiestrogens (fulvestrant [Faslodex]),
luteinizing hormone-releasing hormone agonists (leuprolide, goserelin [Zoladex]), and
aromatase inhibitors (anastrozole [Arimidex], letrozole [Femara], exemestane
[Aromasin]).2 Currently, there are several other options for the treatment of breast cancer,
including surgery, radiation, and chemotherapy. Endocrine therapy is an effective
treatment strategy for breast cancer and is responsible for a significant reduction in breast
cancer mortality. However, while approximately 70% of newly diagnosed breast cancers
express the estrogen receptor (ER), up to 50% of these do not respond to the above
endocrine therapeutic agents 15-17. Furthermore, after a certain period of treatment with
antiestrogens or aromatase inhibitors, breast tumors can become resistant to these agents.
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Along with the acquired form of resistance, there is also “de novo,” or primary,
resistance. The mechanisms of acquired AE and de novo resistances are not completely
understood, and are likely quite complex. Tamoxifen and other AEs are thought to
prevent cancer through their actions at the ER. These compounds also scavenge free
radicals and block the metabolism and redox cycling of estrogen, so other mechanisms of
action cannot be ruled out.18 Another scenario is that the ER is functional and driving
estrogen-dependent processes with the exception of growth. This would indicate that
other independent pathways are stimulating growth. In this case, estrogen-deprivation
therapies would reduce expression of classically estrogen-regulated genes, but not those
associated with cellular proliferation. This phenotype has been observed in ER-positive
tumors treated with neoadjuvant letrozole.19, 20

These findings suggest that nuclear ER genomic signaling pathways do not solely
regulate estrogen-dependent growth of cells. Both estrogen and AEs cause the production
of ROS.3, 9 As a known signaling molecule and second messenger, ROS has the potential
to make dramatic changes in cell cycle progression. While there are systems in cells to
counteract this production, the chronic exposure of cells to low to medium levels of
oxidants can lead to a shift in the “normal” environment of the cell. In the pro-oxidant
state of cells (i.e., high oxidative stress), the balance of thioredoxin (Trx) status is shifted
towards the oxidized form of Trx. There are several studies showing indirect evidences in
support of the concept that high expression of oxidized Trx may be associated with drug
resistance in primary breast cancer.21, 22 In this review, we will discuss the role of Trx in
AE resistance in breast cancer and recent studies in this area. First, estrogen’s and AE’s
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actions are reviewed in brief. Then the role of AE-induced generation of oxidants and
emerging data on the ability of AE-induced RO/NS to modify Trx-mediated redoxsensitive signal transduction pathways are discussed.

2. Mechanisms of estrogen actions in breast cancer
In order to understand the AE actions in cells, it is important that we understand estrogen
actions in normal breast epithelial and cancer cells. Therefore, we have briefly
summarized here estrogen actions. It is widely recognized that estrogen promotes preneoplastic and malignant growth via interaction with estrogen receptors alpha and beta
(ERα and ERβ). This interaction then can lead to transcription either by directly binding
to estrogen response elements, or through non-genomic pathways. The non-genomic
action of estrogen very often includes ligand-binding to the ER at the plasma membrane,
and leads to the activation of signaling pathways such as MAPK, protein kinases A and
C, and calcium pathways,23 initiating a cell signaling sequence that leads to proliferation.
Another non-classical action of the ER is its direct binding to AP-1. When the DNA
binding domain of mouse ERα is mutated, there is an interaction with Jun, an AP-1
coactivator.24 In MCF-7 breast cancer cells, estrogen has been demonstrated to activate
the growth regulatory gene cyclin D1 by 2 to 3 fold. It has also been seen that estrogen
can upregulate c-jun and c-fos in this cell line, which can combine to bind and activate
AP-1 sites on DNA.25, 26 Other studies, however, present that estrogen creates increased
AP-1 activity without the expected increase in c-fos and c-jun synthesis, implying that
estrogen activates, but does not synthesize, other proteins that activate AP-1.27 Estrogen
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activates transcription factors such as NF-κB, and CREB. Estrogen actions through ER
have been extensively reviewed; therefore we have limited our discussion in this area.

More recently, a new mechanism of estrogen action in breast cancer cells has emerged.
Estrogen produces intracellular ROS rapidly, which can lead to cell signaling, and
oxidants contribute to the growth of estrogen-dependent breast cancer cells.28 29
Importantly, the ROS produced in breast cancer as a result of estrogen stimulation does
not require estrogen receptors, as the ER-negative cell line MDA-MB 468 produces a
similar amount of ROS as the ER-positive cell lines MCF-7, T47D, and ZR75.9 It has
also been demonstrated that estrogen is able to stimulate growth in the non-ERexpressing cell line HEK293. This ER-independent growth shows that other factors are
involved in estrogen-stimulated cell growth, and further studies have implicated
mitochondrial ROS formation.30 Free radical generation by estrogen has been
demonstrated, as has the instigation of redox cycling in both stilbene and catechol
estrogens. The damage that can occur due to these estrogen-induced free radicals can lead
to DNA strand breakage, 8-hydroxylation of purine bases of DNA, and lipid
hydroperoxide-mediated DNA modification.9, 12, 31 Redox cycling of estrogen is a delayed
event, because estrogen has to be first metabolized to catechol estrogens to participate in
redox reactions. In the cells of target tissues, there has to be free catechol estrogen
available to participate in redox reactions. Hydroxylated estrogens do not cause the rapid
production of ROS intracellularly through redox cycling, as the metabolites and the
adducts of these hydroxylated estrogens are not seen immediately after E2 treatment,
while the ROS are.9
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There is evidence in support of the concept that: i) Physiologically achievable 17βestradiol (E2) concentration of 1 nM, which corresponds to the estrogenic menstrual
peak, induces rapid formation of mitochondrial ROS in MCF-7 cells. We and others have
also shown similar findings in MDA-MB-231 and other ER-negative cells, indicating that
ER status is not relevant to this effect.32-34 ii) Overexpression of biological ROS
scavengers (e.g., MnSOD and catalase), treatments of cells with chemical antioxidants,
(e.g., N-acetylcysteine and ebselen) or silencing of mitochondrial biogenesis (source of
ROS), inhibits estrogen-induced colony formation in MCF-7 cells. This suggests that
estrogen-induced mitochondrial ROS promote in vitro tumor formation in breast cancer
cells. iii) The expression of early cell cycle genes (such as cyclin D1, D3, E1, E2, and
B2) as well as PCNA, PRC1, and bcl2 that are normally induced by estrogen, were
inhibited by the addition of mitochondrial blockers. This is important because neither
antioxidants nor mitochondrial blockers have presented with ER binding. As such, it
suggests that the transition from G1 to S in estrogen-exposed cells is modulated by
mitochondrial ROS.35 Figure 1-LR shows the different pathways of estrogen-mediated
cell growth.

Recently estrogens have been implicated as antioxidants through scavenging lipid
peroxyl radicals and thus interrupting lipid peroxidation. They also scavenge hydroxyl
radicals at higher levels, and can inhibit superoxide radical generation.36 Estrogen inhibits
the apoptotic oxidative effects of TNF- α (ROS generation, lipid peroxidation,
antioxidant enzyme consumption and disruption of mitochondrial membrane potential).37
Estrogens are phenolic chemicals. In the presence of an oxidant-generating environment,
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the phenolic hydroxyl group present at the C3 position of the A ring of estrogens or
catechol estrogens can readily accept electrons, and can become oxidized by either
accepting these electrons or losing a proton. This can explain the anti-oxidative function
of estrogens.31, 38, 39 There are structural similarities between estrogens and Vitamin E in
terms of an aromatic ring. A hydroxyl group in both compounds donate a hydrogen atom
to reduce free radicals, which allows estrogens and vitamin E to act in an antioxidant way
in the presence of an oxidative environment. Additionally, it has been suggested that
estrogen exerts its antioxidative actions through suppressing inflammatory cytokines or
modulating antioxidant enzyme status.40, 41 In support, there is a link between cell
viability that is enhanced by the estrogen receptor and thioredoxin expression. This was
shown through inhibiting thioredoxin reductase, and noting a reduction in
cytoprotection.42 This was also explored in bovine aortic endothelial cells, and found that
17β-estradiol increased the levels of thioredoxin, glutaredoxin, and thioredoxin reductase.
Tamoxifen treatment inhibited the induction of these three proteins.43

In summary, these studies suggest that estrogen-generated oxidants, together with an
estrogen-driven increase in epithelial cell proliferation, may initiate and promote
neoplastic lesions in estrogen-sensitive tissues. As such, the importance of the ROS
generated by estrogen cannot be ignored when exploring antiestrogen resistance.

3. Actions of endocrine therapeutic agents
The actions of endocrine therapy are primarily based on either lowering ER function or
reducing the levels of circulating free estrogens. Molecular mechanisms of actions of
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individual endocrine therapeutic agents have been extensively reviewed; therefore we
have limited our discussion in this area here. Tamoxifen is one of the effective endocrine
therapies for breast cancer that promotes a conformational change in the estrogen
receptors that effectively blocks coactivator binding, and restricts AF-2 (a protein found
in early G1 phase cells)-induced transcription. However, it also acts as an agonist on AF1-dependent genes.26 As AF-1 and AF-2 are tissue specific,44 this could explain the
tissue-dependent dual antagonistic/agonistic roles of tamoxifen.26 While tamoxifen is a
breast cancer antagonist, it also has agonistic qualities in the uterus and bone. It is
through this duality that tamoxifen is called a selective estrogen receptor modulator
(SERM).45 Tamoxifen’s role as a non-steroidal estrogen antagonist allows it to inhibit
proliferation and induce apoptosis of breast cancer cells.46 This was demonstrated with
the use of ER-positive MCF-7 cells and ER-negative MDA MB-231 cells in which
tamoxifen (5-7uM) induced rapid (within 60 minutes) breast cancer cell death.3 It has
been noted that tamoxifen will act as an estrogen agonist in the non-genomic, membranebound ER pathways, where ER activates kinases such as Src, PI3K, MAPK, EGFR
(epidermal growth factor receptor) and ErbB2. The levels of these kinases play a role in
this, however. Thus if cancer cells express low levels of EGFR and ErbB2, for example,
the membrane ER function, and thus tamoxifen’s agonistic effects, on these tyrosine
kinase receptors may be slight.26

Tamoxifen has also been shown to be a potent antioxidant in certain cells. While its
actions in breast cancer cells lead to cell death, it offers neuroprotection after middle
cerebral artery occlusion. Tamoxifen effects in this disease are thought to be through
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agonistic actions on ER and antioxidant actions. Just as estrogen can be an antioxidant to
low-density lipoproteins (LDLs), tamoxifen and raloxifene are also able to decrease the
oxidation of LDLs.18 A similar antioxidant effect on LDLs is seen in human umbilical
vein endothelial cells.47 Tamoxifen also has presented with antioxidant qualities in
myocardial ischemia-reperfusion (I/R) injury. In rats with induced I/R injury there was a
significant decrease in glutathione and glutathione peroxidase as compared to rats that
also had tamoxifen treatment.48 With focal cerebral ischemia, the antioxidant effects of
tamoxifen may be due to an increase in manganese superoxide dismutase (MnSOD)
levels and a subsequent decrease in the activation of kinases and caspase-3, which are
downstream of superoxide production.49 In the uterus, tamoxifen increases superoxide
dismutase (SOD) activity, and decrease NADPH oxidase (a superoxide generator)
activity.50 Tamoxifen is derived from the estrogen-mimetic hydrocarbon stilbene, and the
stilbene structure can act as a substitute for estradiol. In the presence of an oxidant
generating environment, tamoxifen can readily react quantitatively with hydroxyl free
radicals, and this can explain the anti-oxidative function of tamoxifen.51

When tamoxifen is present alone in cells it can lead to the formation of ROS in breast
cancer cells. While tamoxifen induces breast cancer cell death, it also results in an
increase of ROS production by 1.7 to 2.0 fold. Tamoxifen has rapid non-genomic effects
such as releasing cytochrome c, decreasing mitochondrial membrane potential (Δψm),
and increasing ROS.52 Tamoxifen also is known to inhibit the mitochondrial electron
transport chain.53 Studies have shown that tamoxifen decreases the Δψm and rapidly
releases mitochondrial cytochrome c in p53-negative breast cancers.3, 54 This occurs
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through the stimulation of mitochondrial nitric oxide synthase and the ensuing decrease
in mitochondrial respiration and release of cytochrome c.55 This release is accompanied
by ROS production, leading to oxidative stress in the cell.28, 29, 56 This oxidative stress
may then lead to apoptosis, as it has been suggested that this disruption of the function of
the mitochondria may play an important role in tamoxifen’s fast death response.52
However when inhibitors of complexes I, II, or III are added to HepG2 cells, the levels of
ROS and apoptosis that are typically induced by tamoxifen are not altered significantly.
This is also true when the mitochondrial uncoupler carbonylcyanide-p(triflouromethyoxy)phenylhydrazone (FCCP) is used.57 A novel use for tamoxifen
utilizing its ability to produce ROS was seen when tamoxifen was used as a carrier for
iron (ferrocene). When tamoxifen delivered the metal to tumor cells, the iron interacted
with the hydrogen peroxide already present, and resulted in large amounts of hydroxyl
ions and hydroxyl radicals, which then induced apoptosis in the cell. In this way the high
amount of hydrogen peroxide in tumor cells was used as a prodrug for treatment.58

Another SERM that works in a similar way to tamoxifen is raloxifene. Raloxifene also
binds to the estrogen receptor, and its affinity for it is similar to that of estrogen. While
the bond with the ER creates a change in the special configuration of the ER that
prohibits both activation of and binding of estrogen to the ER, it also contains a
peculiarity in its binding that allows it to block AF-2 interactions, which some say is the
key to its ability to be an estrogen antagonist in both breast and uterine tissues. This
interaction of raloxifene and the ER are quite different in bone and non-reproductive
tissues where it acts as an estrogen agonist through the use of helper/adapter proteins.59
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A more “pure” estrogen antagonist is ICI 182780, or fulvestrant. Fulvestrant acts in three
ways on the ER. First, in binding to the ER, it impairs the ability of the ER to dimerize as
well as its ability to move into the nucleus. It also disables the ER activation functions of
AF1 and AF2, which recruit coactivators and other necessary proteins to the
transcriptional complex, both of which are necessary for estrogen agonistic activity. And
lastly, when fulvestrant binds to the ER, the complex becomes unstable, which leads to
an accelerated degradation of the ER protein, though not of ER mRNA.60

The prototype SERM (tamoxifen) and its derivatives (toremifene, droloxifene, and,
idoxifene), the second-generation SERM raloxifene, the third-generation SERM
arzoxifene, and the fourth-generation SERM alcolbifene undergo metabolic activation
and their metabolites are more capable of participating in redox reactions. 61, 62

The ER-mediated actions were identified initially as a pathway blocked in AE-treated
cells, and inhibition of this pathway causes permanent growth arrest/cell death. Reactive
oxygen species, a byproduct of oxidative processes, can induce an irreversible growth
arrest similar to SERM antiestrogens. SERMs are capable of producing ROS through
their metabolic activation. These findings suggest that SERMs may mediate growth arrest
by a mechanism involving ROS accumulation.61, 62

Third-generation aromatase inhibitors (AIs), such as anastrozole, letrozole, and
exemestane that have a non-steroidal structure, also play a role in breast cancer treatment.
As their name implies, AIs prevent conversion of androgen to estrogen by inhibiting
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aromatase enzyme activity in the cells. Thus AIs inhibit the mitogenic response in the
breast tissue by inhibiting both estrone (E1) and estradiol (E2) production.63 While firstand second-generation AIs have been found to be quite effective, the side effects have
caused the use of them to be controversial. Third-generation AIs, on the other hand,
appear to have complete specificity without adrenal axis affects. AIs are used on women
with ER/PR expression, but who do not have functional ovaries or who are premenopausal. The amount AIs lower estrogen expression in those who do not fit this
description is not enough to have an effect on tumor growth.64

In summary, antiestrogen-mediated oxidative stress has received attention as an ERindependent mechanism. Like stilbene estrogen, tamoxifen and its metabolites produce
ROS, which can lead to oxidative damages to macromolecules, such as lipids and
DNA.65-68 Like tamoxifen, other SERMs can also participate as substrates in metabolic
redox reactions, which in turn can also produce oxidative stress.61 This increase in redox
reactions could lead to a more oxidized state of the breast cancer cell, leading to cellular
adaptation to ROS signaling, and a new cellular state that allows cell cycle progression in
the presence of tamoxifen and possibly other SERMs.

4. Overview of existing paradigms of antiestrogen resistance
A major problem with the use of antiestrogens is the prevalence of resistance, either at
the outset of treatment or after continued use. De novo, or primary, resistance can occur
when tumors do not express estrogen or progesterone receptors.69 70, 71 As most
estrogenic actions are considered to be mediated through the ER, lack of this protein
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causes an inherent resistance to endocrine therapies,72 but this does not explain the 4050% of people who do not respond to treatment despite steroid hormone receptor
expression.73 A more recent discovery in de novo resistance is inactive alleles of
cytochrome P450 2D6. This allelic inactivity keeps patients from being able to convert
tamoxifen to its active metabolite, endoxifen, leading to a decreased response to
tamoxifen. Patients who initially respond to antiestrogen treatment often become resistant
to the drug within 2 to 5 years.26 The decreasing sensitivity of ER-positive breast cancer
cells to antiestrogens with time is caused by several factors, and different mechanisms
have been proposed to explain antiestrogen resistance. Since mechanisms of AE
resistance have been widely reviewed,72 we have briefly summarized them here.

Cross talk between ER and growth factor signaling has emerged as one of the important
mechanisms in endocrine resistance. Since ERα expression plays a key role in predicting
the response a patient will have to hormonal therapy such as antiestrogens,69 it is
considered that a loss of ERα expression would be responsible for an acquired resistance
to antiestrogens. Most data is related to tamoxifen treatment,69 and it shows that only
approximately 17-28% of patients with acquired resistance to tamoxifen have a loss of
ERα expression.26 There is also the possibility of ER mutations causing loss of
functionality, or that the ER continues to drive all estrogenic actions except growth.72 But
again, fewer than 1% of ER positive tumors have been found to have ERα mutations.74
Another possibility lies in a truncated version of ERα, ERα36. When ERα36 is in the
presence of the full ERα, there is decreased responsiveness. Posttranslational
modification of ERα regulates its function as well as its interactions with other proteins
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such as ERα co-regulators. Co-regulators include AP-1 and NF-κB, and phosphorylation
and overexpression of these co-regulators can cause an increase in ERα-mediated
transcription, which has been associated with endocrine resistance.74

Mechanisms different from the ER have been proposed in antiestrogen resistance, with
ErbB2 overexpression being the best characterized. Breast cancers that are resistant to
tamoxifen have shown an increase in the expression of receptor tyrosine kinase (RTK)
members, such as epidermal growth factor receptor pathway members like ErbB1 and
ErbB2.75 76 When ErbB1 and ErbB2 (also known as HER-2) are overexpressed, they can
reduce the levels of the cyclin-dependent kinase inhibitor p27 and inhibit its function, and
thus keep tamoxifen from activating this molecule to keep the cell in G1 arrest.76 Not
only does Her2 overexpression contribute to resistance on its own, but Her2 dimerization
with other members of the ErbB receptor family can also lead to antiestrogen resistance.77
Overexpression of other tyrosine kinases, such as Src kinase family members, is seen in
breast cancer, and has been implicated in resistance through its substrate BCAR1.74

Overexpression of cell cycle proteins such as Myc and cyclin D1 is associated with
tamoxifen resistance, as is a decrease in expression of the NF-κB-binding interferonresponsive putative tumor suppressor, IRF1.74 Response to tamoxifen is also correlated
with the expression of the MAPK inhibitor, MAPK phosphatase 3 (MKP3), with resistant
cells expressing increased levels of MKP3.78
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Current hypotheses in tamoxifen resistance do not include the effect of a chronic
exposure to ROS that is created by tamoxifen. Certainly tamoxifen is not known to
work through a ROS-mediated pathway, but it does increase ROS. As such, the longterm exposure of breast cancer cells to tamoxifen- (and estrogen-) mediated ROS
production may play a role in tamoxifen resistance. In the following section we explore
this novel hypothesis.

5. Redox signaling and antiestrogen resistance
Before we discuss the role of redox signaling in antiestrogen resistance, we would like to
briefly introduce the basic conditions that produce changes in the redox state of cells,
generation of ROS and concepts of redox signaling.

Redox state of cells: Historically, the term redox state has been used to describe the ratio
of the interconvertible oxidized and reduced forms of a specific redox couple. The three
major redox couples in cells are NADP+/NADPH, GSSG/2GSH, and TrxSS/Trx(SH)2.
These redox couples are not isolated systems; rather they are thermodynamically
connected to each other in the maintenance of redox equilibrium of cells. For example,
both the Trx and GSH systems use NADPH as a source of reducing equivalents,79 and a
decrease in thioredoxin reductase affects glutathione reductase activity in glucocorticoidresistant Alopecia areata.80 Redox couples in cells are responsive to electron flow, that is,
changes in the reducing/oxidizing environment. When the products of the reducing
capacity and the reduction potential of a linked set of redox couples in cells or tissue are
added, it is considered the redox environment.79
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As is true with the control of pH within the body, the redox environment is well governed
through what is known as redox regulation. In this process, redox homeostasis is
disturbed by increases in the formation of ROS or decreases in the actions of antioxidant
systems. This imbalance towards oxidation allows for redox signaling to occur. When
pathological conditions are present, however, these oxidizing conditions can accumulate
and have the potential to cause changes in cell signaling, which is commonly seen in
disease states.81

When a cell loses its capacity to reduce redox couples,82 there is a higher production of
ROS or reactive nitrogen species, which result in a production or reaction from the
antioxidants and reducers within the cells. This is explained below.

Reactive oxygen species (ROS) is a term extended to a range of molecules, including free
radicals (which contain one or more unpaired electrons) and include superoxide (O2·-),
hydrogen peroxide (H2O2), hydroxyl radical (OH), and peroxynitrite (ONOO-).83 Several
enzymatic systems and organelles create ROS, such as NADPH oxidase complex,
cytochrome 450, nitric oxide synthases, xanthine oxidase, peroxisomes, endoplasmic
reticulum and mitochondria.84, 85 The mitochondria, however, are the largest source of
ROS in epithelial cells,29 and most ROS in endothelial cells are developed in the
mitochondria through the electron transport chain.83 ROS are created when oxygen (O2)
is put through an oxidoreduction conversion in the mitochondrial electron transport chain.
There are four complexes relating to this chain through which electrons travel; the
electrons are accepted by complex I (NADH-ubiquinone oxidoreductase) from NADH.
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The electrons then move to complex II, succinate dehydrogenase. At this complex, the
succinate is oxidized to fumarate, and the electrons continue to complex III, ubiquinolcytochrome c oxidoreductase, and then to complex IV, cytochrome c oxidase. When they
finish the travel through all four complexes, they reduce molecular oxygen to water.
Throughout this process, however, a small amount (1-4%) of the oxygen is not fully
reduced and results in O2·-. This release of O2·- from the transport process occurs mainly
at complexes I and III, with complex I-generated O2·- being released only into the
mitochondrial matrix, and complex III- O2·- being released into both sides of the inner
membrane of the mitochondria.86

The enzymes that reduce proteins or destroy ROS are as important players as the ROS
themselves.87 When there is a production of ROS within the cells, there is the reaction of
the production of antioxidants. This is called redox (reduction and oxidation)
regulation.81 There are several antioxidant systems, both enzymatic and non-enzymatic,
in place to counteract redox imbalance. Enzymatic systems include superoxide dismutase
(SOD), catalase, peroxiredoxins and glutathione peroxidase, while non-enzymatic
systems include glutathione, thioredoxin, and vitamins C and E.88 Superoxide does not
easily diffuse across the membrane of the mitochondria. While mechanisms do exist for
this to occur (voltage dependent anion channels), SOD can reduce the superoxide to
hydrogen peroxide (H2O2), which does easily cross the membrane.81, 86, 89 SOD has three
isoforms; copper-zinc (CuZnSOD) in the cytoplasm, nucleus, and mitochondrial
intermembrane space, a second form of CuZnSOD in the extracellular space, and
magnesium SOD (MnSOD) in the mitochondrial mix. While they serve similar functions,
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MnSOD appears to be highly important physiologically, for it’s genetic removal is
embryonically lethal.86 Once SOD has changed the O2·- to H2O2, catalase and glutathione
peroxidase within the cell can then reduce the H2O2 to water, or, in the presence of
transition metals, to the hydroxyl radical (OH-).86 81, 89 Figure 2-LR summarizes the major
mammalian ROS and antioxidant systems. For a more in depth discussion on these
processes see88,90,91.

Reactive oxygen species as signaling molecules: ROS are known signaling molecules,
meaning there is a stimulus and a response to the ROS from a protein of either activation
or inhibition. This response is amplified through the activation or inhibition of effector
molecules further downstream in the pathway, and there is reversibility so that the
pathway can be responsive to more than just the one stimulus. While not all ROS
modifications are regulatory in function, glutathione and thioredoxin, as well as enzymes
that are associated with each, have been found to reduce the thiol oxidation that occurs
through ROS. It has been compared to the regulatory effect of phosphorylation and dephosphorylation of proteins.92

ROS can instigate both apoptosis and cell proliferation, depending on the dose.25, 93 For
example, in HT-29 colon cancer cells, toxic levels of H2O2 (1,000 uM) lead to apoptosis,
while lower doses, (10 uM) induce cell proliferation.94 And when MCF-7 clones
overexpress IL-1β, which leads to a high IL-1β output and thus a high ROS generation,
cells undergo apoptosis. When, however, a moderate level of IL-1β is secreted in these
clones, it leads to clonal expansion.9 Mitochondrial ROS have been implicated in cell
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signaling in several pathways, including integrins, platelet-derived growth factor,
epidermal growth factor, and nerve growth factor.95 When the cells undergo stress such
as chronic inflammation (often from infections) and chronic chemical insults (such as
tobacco smoke), there can be a transformation of the cell due to the ROS created by these
irritants. This transformation often causes a lack of cell cycle regulation at cell cycle
checkpoints. As such, the cells will overexpress growth factors that are oncogenic,
leading to cell proliferation.96 In a number of cell lines, hormones, cytokines,
neurotransmitters and growth factors can instigate cell signaling97 through inducing a
low-concentration oxidative burst that may lead to signal initiation.98 For example, in
endothelial cells, TNF-α, IL-1, bradykinin and thrombin can generate superoxide, and
TGF-β1 and bradykinin can generate H2O2. These ROS are created to mediate mitogenic
signaling, to regulate gene expression, to induce mRNA, and to move the cell cycle
progression from G0/G1 to S phase.95 ROS produced by the estrogen-induced cytokine
Interleukin-1β can lead to cell proliferation through AP-1 and NF-κB binding sites and
through the MAPK/AP-1 and ROS/NF-κB pathways.99 Estradiol can lead to an
overexpression of IL-1β in MCF-7 cells, which then leads to cell proliferation. When
these cells are exposed to antioxidants and mitochondrial blockers, both a decrease in
cyclin D1 expression and a suppression of cell growth can be seen.100 In a study of MCF7 cells treated with 17β-estradiol and insulin-like growth factor, it was shown that the
combination of these elements increased peroxide production.101 The role of
mitochondrial ROS production in regards to signal transduction can be seen in HeLa cells
that lack mitochondrial DNA, which show a reduced ROS level, as well as a decrease of
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cell cycle progression at all phases, and a decrease in certain cell-cycle regulators such as
p21 and p27. This decrease is attributed to the lack of ROS production.102

The apoptotic effect of cytotoxic levels of ROS is one way in which mitochondria play a
role in chemotherapy-induced apoptosis.96 Camptothecin, mechlorethamine, and
doxorubicin all induce apoptosis in breast cancer cells.103 Other ROS-utilizing
chemotherapies include epirubicin, topotecan, and cisplatin.104 Dicumarol, an
anticoagulant that creates oxidative stress and induces cytotoxicity in human pancreatic
cancer cells, is thought to work through the electron transport chain in the
mitochondria to create superoxide and hydrogen peroxide. This action of increasing
cytotoxicity in these cells is decreased in pancreatic cancer cells that do not express
functional mitochondria.105

Redox signaling: Redox changes in the cell are critical for initiating various signaling
pathways [see above]. Three of the major cell signaling pathways involve: (i) protein
phosphorylation, (ii) protein acetylation or (iii) protein thiol status change that occurs
because of alterations in cellular redox environment. Change in the thiol status of the cell
can be triggered by both oxidants and reductants. We now know that signal transduction,
DNA and RNA synthesis, protein synthesis, enzyme activation, cell cycle regulation,
ligand binding, DNA binding, and nuclear translocation are altered by changes in the
cellular redox environment. Most eukaryotic transcription factors such as AP-1, NF-κB,
and Sp-1106 and glucocorticoid107 and estrogen receptors108 are affected by the redox
environment. They must be in their reduced form to be active, and their translocation to
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the nucleus is often redox-dependent.79, 106 We discuss below the molecular mechanisms
of redox signaling in more detail.

As a known signaling molecule and second messenger, ROS has the potential to make
dramatic changes in cell cycle progression. As mentioned earlier, high levels of ROS can
lead to apoptosis while low levels can lead to cell cycle progression. Yet another action
of ROS includes cell adaptation to chronic exposure of low to moderate levels.
At moderate levels, ROS can use reversible protein oxidation to regulate signaling
pathways. The common foci of this are protein kinases and transcription factors. This
regulation can lead to an adaptation of the cell to changes in its environment.109 For
example, when renal cells are exposed to oxalate, the initial reaction is cell death, but
after 48-72 hours they can adapt to the exposure and begin to grow.110 In muscles, it has
been suggested that exercise-induced ROS, as well as muscle-derived cytokines, play a
role in muscle adaptation to exercise.111 The treatment of cisplatin on HepG cells
increases ROS tremendously, with levels returning to normal after 120 hours. At the
same time, the mitochondria membrane potential changes, but then also returns to normal
by 120 hours despite continued exposure. It is suggested that this occurs due to the cells
adapting to the experience of cisplatin exposure.112

This adaptation to ROS could play a role in breast cancer resistance to tamoxifen. As
tamoxifen is known to increase levels of ROS and this increase is not at a high level that
leads to apoptosis, there appears to be a low to medium exposure of cells to tamoxifenrelated ROS. The ROS produced may alter cell signaling, and the cell may begin to adapt
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to this new signaling function and learn to grow in the presence of tamoxifen. Figure 3LR summarizes these ROS actions in the cell. In the next sections we discuss possible
protein adaptations that can occur from this constant exposure to ROS via tamoxifen.

Redox regulation of protein tyrosine phosphatases/kinases: Along with the
alteration of transcription factors and certain receptors, the modification of protein
phosphatases and kinases by ROS must also be considered.113 Cell proliferation,
differentiation, activation, homeostasis and apoptosis are all furthered by tyrosine
phosphorylation, as well as threonine and serine phosphorylation (though these play a
lesser role). This phosphorylation is regulated by protein tyrosine kinases and protein
tyrosine phosphatases.114

Protein-tyrosine phosphatases (PTPs) are a part of the family of cysteine-based
phosphatases. ROS plays its role most especially in PTPs, which have a signature motif
made up of a cysteine, five X (any) amino acids, and Arginine (Cys-Xaa(5)-Arg). This
motif allows for redox regulation of proteins when the cysteine residues react with
ROS.115 The PTP catalytic cysteine, which remains as an etiolate anion (Cys-S-) under
reducing conditions, only requires mild oxidative conditions to be oxidized to sulfenic
acid (Cys-SOH). Once in this oxidized form, there is a continued vulnerability to ROS,
and it can become terminally oxidized as sulfinic (Cys-SO2) and sulfonic (Cys-SO3)
acids. This can be averted by interactions with a protein structure such as a thiol. This
interaction can protect the cell through creating an inter- or intra-molecular disulfide
bond that does not allow any other reactions to occur at the catalytic cysteine.87, 115-117
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The counter proteins to PTPs are protein tyrosine kinases (PTKs). An important role of
PTPs and PTKs is their ability to turn on and off the action of the protein on which they
are exerting their influence.117 The PTP’s common active motif exists as a thiolate,118
which allows PTPs to perform their dephosphorylation activity on phosphoproteins or
phospholipids. Oxidation of PTPs can be reversed by thiol compounds118 once the
catalytic cysteine forms a disulfide bond with an N-terminal cysteine. This disulfide bond
can originate from same site cysteines, as is the case with low molecular weight PTPs,119
from “distant” cysteines such as with PTEN and cdc25,120 or from a bond between the
PTP and a thiol, such as with PTP1B.121 The important step of the disulfide bond blocks
the oxidation of the thiolate to Cys-SOH by connection to another thiolate. Oxidation and
phosphorylation have the potential of influencing each other in the signaling of PTPs and
PTKs. It is suggested that one may actually be a preparatory modification for the other.
For example, PTP phosphorylation can increase the catalytic activity of the protein. This,
in turn, opens the protein to oxidation.118

The reversibility of PTP oxidation is critical to cell signaling response. It has been
suggested that at physiologic levels, one of the roles of ROS is to oxidize PTPs to
encourage redox signaling.122 Structural changes to PTPs, as well as serine/threonine and
phospholipid phosphatases, are induced by ROS, and the altered protein conformation
leads to signaling cascade upregulation. Included in these cascades are growth factor
kinase-dependent, src/Abl kinase-dependent, MAPK-dependent, and PI3 kinasedependent pathways, leading to activation of AP-1, NF-κB, HIF-1, and other redoxregulated transcription factors.88
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Redox regulation of transcription factors: Certain transcription factors such as AP-1
and NF-κB are known to be redox regulated.106 AP-1 is a heterodimeric transcription
factor that has been found to regulate cell proliferation, death, survival, and
differentiation,123 depending on several factors. These factors include the balance of
target genes that are either pro- or anti-apoptotic, the type of stimulus that induced the
AP-1, and the persistence of that stimulus.88 The components of AP-1, c-Jun and c-Fos,
can be induced by reactive radicals, and can positively regulate proliferation.88

Because of their regulatory actions on transcription factors, most especially MAPkinase/AP-1 and NF-κB, ROS are able to alter cell proliferation, differentiation, and
apoptosis.81, 124, 125 Since certain cell cycle genes contain response elements for these
transcription factors, ROS can activate these genes and lead to cell proliferation.126 ROS
actions regarding these transcription factors can be different depending on the cell line,
however. For example, H2O2 is known to activate NF-κB,127 and in cardiovascular
vessels, ROS activates AP-1 and NF-κB.128 In normal melanocytes, oxidative stress can
be “suppressed” without the recruitment of NF-κB and AP-1. In melanoma cells, on the
other hand, redox changes easily recruit NF-κB and AP-1. In these cells, NF-κB is
correlated to H2O2 and not superoxide, and AP-1 to superoxide anion and not H2O2.129
AP-1 can, however, be induced by H2O2 in other cells, mainly through the JNK and p38
MAPK signaling pathways. This can be done through either ASK1 (apoptosis signalregulating kinase 1, which is released on thioredoxin oxidation as discussed below) or
through the inhibition of MAPK phosphatases (which in turn leads to increased kinase
activity).88 In tamoxifen resistant breast cancer, oxidative stress is implicated in an
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increased AP-1 DNA binding with c-JUN NH2 terminal kinase activity in tamoxifen
resistant breast cancer.68, 130, 131

Reactive oxygen species are significant outcomes of estrogen and tamoxifen actions in
cells. Tamoxifen resistance has an association with oxidative stress in breast cancer cells,
and this leads to an increase in c-Jun and phosphorylated JNK levels, as well as an
increase in AP-1 activity. A significant decrease in glutathione levels has been shown in
tamoxifen resistant MCF-7 xenograft tumors, though there is an increase in SOD and
glutathione S-transferase levels.68 And when vitamin E is added to tamoxifen-treated
breast cancer cells, cell proliferation and ERK phosphorylation, which are normally
decreased with tamoxifen treatment, are restored.132 It is with this in mind that we now
discuss the thioredoxin system.

Thioredoxin system and redox regulation: For this review, our focus is not on the
mechanisms of antiestrogen treatment, but rather the resistance that occurs with
treatment. To explore how redox regulation may play a role in antiestrogen resistance, we
will discuss the possible involvement of thioredoxin and the thioredoxin family. In the
following section we discuss the role of ROS in Trx oxidation, and then a potential role
in tamoxifen resistance.

Thioredoxin (Trx) is a 12 KD disulphide reducing enzyme that is excreted by a variety of
cells.133, 134 The importance of thioredoxin can be seen with its role within the DNAbinding sites of several transcription factors, where it reduces cysteine moieties and thus
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plays a role in gene expression.135 There are five cysteines in Trx (32, 35, 62, 69, and
73),136 two of which (32 and 35) are in the highly conserved domain of redox
regulation137 with the sequence Trp-Cys-Gly-Pro-Cys.106 There are three forms of Trx;
Trx1 (herein called Trx) that is cytosolic, the mitochondrial form (Trx2), and a third
(SpTrx) that is found in spermatazoa.138 The cytosolic mammalian Trx, lack of which is
embryonically lethal, has numerous functions in the defense against oxidative stress,
control of growth and apoptosis. It also has co-cytokine and chemokine activities.139
Thioredoxin is secreted in times of oxidative stress and inflammation in both normal and
neoplastic cells.139 It has been suggested that Trx2 may be protective to cells during such
exogenous insults as radiation and certain anticancer drugs.140 It has also been suggested
that Trx2 and peroxiredoxins (Trx peroxidases) regulate the release of cytochrome c.

As discussed above, an important aspect of the redox state is the role of cysteine residues
and thiol chemistry.92 ROS is particularly drawn to cysteine and methionine residues,88
and when these residues are oxidized, they are reduced by thioredoxin and
glutathione/glutaredoxin-dependent reactions.139 Thioredoxin and glutathione are the
major factors in maintaining reduced proteins,81, 139 and these reducing agents are found,
in normal cells, in their reduced form. When they perform their reduction actions on
oxidized proteins, they themselves are oxidized. They are then returned to their reduced
forms through the use of thioredoxin reductase and glutathione reductase, respectively.
Cysteine residues have been found to be specific targets for ROS when in the thiolate (-S)
form, making them susceptible to ROS modification. ROS is drawn to reactive cysteine
residues in target proteins. When the cysteine residue is in the thiol form (-SH) it is not
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highly reactive and requires some catalyst to encourage reaction with a hydroperoxide.
When the cysteine residue is in the thiolate form, however, it can react easily with
ROS.141 Thiol chemistry has been well reviewed, and thus is only discussed in the context
of this paper. For an extensive review, see Forman et al.141

Trx is ubiquitous and has a variety of functions, including gene regulation (such as with
NF-κB and p53), regenerating antioxidant enzymes, and catalyzing antioxidant reactions.
Trx also can indirectly affect MAPKs and phosphoprotein phosphatases. When in the
cytoplasm, Trx functions more as a reducing agent and an antioxidant, whereas in the
nucleus it is a transcription factor regulator.142 In breast carcinomas, immunoreactivity of
Trx in the nucleus is related to p53 positivity and to proliferation, as well as to an inverse
association with estrogen and progesterone receptor status.143

Trx is induced by stressors, including mitogens and H2O2. In stromal cells, both Trx
mRNA and protein are increased with 17β-estradiol treatment. This effect is suppressed
when tamoxifen treatment is given. It is also suggested that Trx might act with EGF,
another secretion of stromal cells upon E2 treatment, as a co-mitogen.144 Intracellular
levels of Trx increase when human skin fibroblasts have been UVA-irradiated, as have,
in a time-dependent manner, Trx mRNA. This irradiation may lead to the translocation of
Trx from the cytosol to the nucleus, and to an increase in thioredoxin reductase.145 In
HIV patients, it has been seen that the loss of CD4+ T-cells by apoptosis is preceded by
depletion of, among other redox molecules, glutathione and thioredoxin. An increase in
ROS and a change in the Δψm are also seen before the T-cell loss.146
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Thioredoxin has been linked to cancer in a variety of ways, and it is associated with
several effects, such as decreased survival and aggressive tumor growth. Cancer cells can
secrete Trx, and there have been reports of high levels of Trx in certain cancers, namely
cervical, hepatoma, gastric, lung, and colorectal. In human leukemia cells and solid tumor
lines, growth can be stimulated by Trx.81

The redox state of Trx is important to its function, and as such, the role of Trx reductase
(TrxR) is key. In both Trx and TrxR there are cysteine molecules that are key to redox
regulation.133, 134 TrxRs are NADPH-dependent, and they catalyze disulfide reduction at
thioredoxin active sites. In turn, reduced thioredoxins catalyze the movement of active
site dithiols to a disulfide state. This process has given the thioredoxin family a crucial
role in cell-growth and apoptosis, as it is through this process they can regulate enzymes
such as ribonucleotide reductase, peroxiredoxins and transcription factors.147

When exposed to oxidants or nitrosothiols, Trx quickly translocates to the nucleus,148 and
acts in the control of transcription factors.149 A growing number of transcription factors,
including NF-κB or Ref-1-dependent AP-1, are showing a need for thioredoxin reduction
for DNA binding.139, 150 123 When Trx is overexpressed, NF-κB is downregulated and AP1 is upregulated and enhanced. Interestingly, while thioredoxin-induced NF-κBNF-κB
inhibition is found in the cytoplasm, Trx can increase NF-κB binding to nuclear DNA.

The TXNRD1 gene encodes for thioredoxin reductase 1, and transcription involves
alternate splicing, and thus leads to several isoforms.151 The three TrxR enzymes that
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have been identified in mammals are TrxR1, TrxR2, and TGR. TGR is expressed mostly
in the testis, and TrxR2 is a mitochondrial form. TrxR1 (herein called TrxR) is the
cytosolic enzyme, and, like Trx, is widely expressed.149, 152 TrxR belongs to the
homodimeric pyridine nucleotide disulfide oxidoreductase class.152 It is a homodimeric
selenocysteine-containing protein, and thus is dependent on selenium for its synthesis.149
82

Selenium (selenite, 1uM) increases the mRNA levels of TrxR by two- to five-fold.149

TrxR has the capability of metabolizing certain selenium compounds, and it is thought
that through this process, TrxR can reduce the active site of plasma glutathione
peroxidase, another selenoprotein.153 TrxR has been found to be elevated in several
cancerous cell lines133, 149 including pancreatic, cervical, hepatocellular, and certain lung
cancers,21 and repressed in cells that overexpress the p53 protein. Several studies have
looked at the rise of TrxR in cancer cells.149

Thioredoxin and thioredoxin reductase work together with NADPH to form a system
that, through redox regulation, control processes such as DNA synthesis, transcriptional
regulation, and cell growth. They also confer resistance to cytotoxic agents that produce
oxidative stress and lead to apoptosis. While thioredoxin is a reducer of proteins that have
oxidized cysteine residues, it also is susceptible to oxidation as it contains one cysteine in
the thiolate form. The reaction of thioredoxin is described as follows:
RS- +H2O2→RSO- +H2O+H+
As is true with other cysteine-based proteins, thioredoxin can create a disulfide bond,
either intramolecularly or with peroxiredoxin. This form of the protein then is not open
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for interaction with other thiols or thiolates, and requires thioredoxin reductase to reduce
its disulfide status. To do this, thioredoxin reductase works with NADPH as follows:
Trx reductase
Trx(S2)+NADPH

→

Trx(SH)(S-)+NADP+

In Trx and TrxR, the redox signal can change the cysteine sulfur molecule from –CH2—
SH to –CH2—S-. This “sulfhydryl switch” allows for changes in the enzymes’ activities.
Once oxidative stress has occurred, the TrxR charges the sulfur atoms on the Trx,
activating the Trx. And once activated, Trx can move from the cytoplasm to the nucleus
where it activates Ref-1, which further activates transcription factors that can protect the
cell from oxidative stress.133

Thioredoxin reductase and glutathione reductase have similar homologies, and also have
some overlap of function. Similarly, thioredoxin and glutaredoxin also have an overlap
of function. Thioredoxins, however, are able to catalyze disulfide reduction much faster
than GSH. 139

Trx family and ROS: There are several published examples of Trx’s susceptibility to
ROS. There is a variety of compounds that have been found to oxidize Trx, such as H2O2,
superoxide,154 paraquat, rotenone,155 and 2-[(1-methylpropyl)dithio]-1H-imidazole (PX12).156 PX-12 (also called IV-2) not only oxidizes TrxR, but also irreversibly inhibits Trx
protein function through cysteine residue oxidation.156 In human lens epithelial HLE B3
cells, when H2O2 treatment was given, Trx expression increased.157 In keratinocytes,
lymphoid, and HeLa cells, H2O2 exposure leads to an increase in Trx mRNA levels.158
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When endothelial cells are exposed to low doses of ROS, (10 and 50 μM H2O2 and shortterm exposure to shear stress), significant increases in Trx mRNA and protein levels are
seen. It follows, then, that there would also be a reduction in apoptosis induction, and
when Trx expression is reduced and low doses of ROS administered, apoptosis is
induced. Thus a portion of the anti-apoptotic nature of low-dose ROS in endothelial cells
could be due to the increase in Trx expression.159

It is thought that lung injury that occurs with bleomycin anticancer therapy is due in part
to ROS. Trx, but not Cu/Zn-SOD, mnSOD, catalase, or glutathione peroxidase is strongly
induced in the lungs of mice treated with bleomycin, suggesting that Trx may modify the
reduction and oxidation state in bleomycin resistance, and perhaps may be protective
against bleomycin-induced lung injury.160

Trx scavenges ROS that has been created by diesel exhaust particles (DEP). While acute
lung disease and an increase in inflammatory cells were seen in control mice, human Trx
transgenic mice appeared to be protected from this injury. L929 cells that had been hTrx1 transfected and A549 cells pretreated with recombinant human Trx were utilized. A
downregulation of the phosphorylation of Akt was shown, which led to apoptosis. This
downregulation and subsequent cell death was prevented by treatment with Trx. It was
also seen that when Akt was inhibited in the cells, the protective effect of Trx was
canceled. These results show that Trx may play a protective role against DEP and
subsequent lung damage via Akt regulation.161
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It is thought that oxidative stress that is present in hyperhomocysteinemia is due to
impaired Trx and subsequent increased ROS.162 Low-dose exposure to 5-aminolaevulinic
acid-based photodynamic therapy (ALA-PDT, a treatment for superficial skin cancer)
increases Trx expression and leads to cell growth, while high-dose exposure showed
apoptosis with minimal Trx expression.163

Trx acts as a cofactor for peroxiredoxins in their role as H2O2 scavengers. Trx and
peroxiredoxin I are elevated in human lung tissues by hypoxia.140 MCF-7 cells that have
been transfected with Trx also have an increase in the expression of Trx peroxidase-1, an
H2O2 scavenger. This expression protects against H2O2-induced apoptosis, but not against
apoptosis induced by anti-cancer drugs such as etoposide and doxorubicin.164 In a study
of 89 non-small cell lung carcinomas, Trx and TrxR were found in all but 3 and 8 cases,
respectively, and were both cytoplasmic and nuclear. When the expression of these
proteins was nuclear, there was an inverse association with apoptosis. When the grade of
the carcinoma was high, there was a decrease in Trx and TrxR expression.165 Thioredoxin
peroxidase II (also known mitochondrial peroxiredoxin 3)166 can decrease H2O2 when
overexpressed, and through this mechanism can inhibit apoptosis.139

The dietary isothiocyanates sulforaphane, erucin, and iberin have been found to induce
thioredoxin reductase in MCF-7 cells.167 In HepG2 and undifferentiated Caco-2 cells, not
only does sulforaphane induce TrxR, but also its substrate Trx.168 Selenium
supplementation increases TrxR activity in high risk prostate cancer patients,169 and
mercury toxicity can lead to the selective inhibition of TrxR.170
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Redox regulation of proteins by Trx: Trx family under- or over-expression has been
related to a number of diseases and their effects, from airway remodeling,171 H. felisinduced gastritis,172 Sjögren's syndrome,173 and angina174 to alopecia areata-based
glucocorticoid resistance,80 decreased cystic fibrosis sputum,175, 176 and ischemiareperfusion injury prevention.177, 178 Trx is also both a biomarker and a therapeutic agent
for cardiac disorders.179 It has been suggested that an increase in Trx in lung transplant
patients can be a biomarker for organ rejection, as a significant increase in Trx was seen
in bronchoalveolar lavage fluid of graft-rejecting patients in an 18-patient study.180
Metastatic colorectal cancer liver resection patients whose metastases were Trx positive
presented with shorter survival than those whose tumors were Trx negative.181 Trx
inhibits the activity of PPARα, a transcription factor in the nuclear receptor family
which is involved with lipid catabolism, and whose genes are targets of lipid lowering
fibrate drugs.182

The majority of studies performed on the thioredoxin family are on its role as an
apoptosis inhibitor. This inhibition has been seen by Trx2 overexpression in SH-SY5Y
human neuroblastoma,183 lung and other cells by overexpression of Trx.184 185 In mice,
TrxR overexpression inhibits apoptotic signaling and gastric ulcer formation that occurs
with the treatment of the non-steroidal anti-inflammatory drug indomethacin.186 For Trx
to suppress apoptosis of cisplatin-treated breast cancer cells, it must be nuclear. In MCF7 cells, when total Trx was increased with no increase in nuclear Trx, there was no
change in cisplatin-mediated apoptosis. There was, however, a decrease in cisplatininduced apoptosis when nuclear Trx was increased with no change in total Trx.187
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This propensity for inhibition has made TrxR a target of certain drugs. TrxR has been
inhibited by auranofin to induce apoptosis in cisplatin-resistant C13* ovarian cancer
cells,188 and by 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)] ethane and
cyclophosphamide to induce apoptosis in several human cancer cell lines.189 190 Green tea
extracts inhibit TrxR in HeLa cells, which also show a concentration-dependent decrease
in cell viability.191 GRIM-12 has been identified as being identical to TrxR, and GRIM12 overexpression increases apoptosis that is interferon/tamoxifen induced. On the other
hand, when GRIM-12 is underexpressed, there is a resistance to interferon/tamoxifeninduced cell death and an increase in cell growth. Thus TrxR may play an important role
in tamoxifen resistance.192

Thioredoxin interactions with other proteins: Thioredoxin interacts with many
different proteins and acts as both an inhibitor and a regulator. One MAP3K protein that
is directly affected by Trx is apoptosis signal-regulating kinase 1 (ASK1).149 In its
reduced form, thioredoxin is known to inhibit ASK1 through binding to the protein.193
However, Trx becomes disassociated with ASK1 in the presence of ROS,193, 194 149, 195
allowing ASK1 to activate the JNK/p38 pathway.140 196

Under reduced conditions, Trx binds to the N-terminus of ASK1. However, upon
oxidation it become dissociated from ASK1.197 Competition with Txnip can also interfere
with Trx/ASK1 interactions.198 The importance of the Trx relationship with ASK1 can be
seen with H2O2 exposure. This exposure leads to the oxidation of ASK1, which can be
reversed by Trx.199 The loss of interaction ASK1 has with Trx upon Trx oxidation has
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been studied in several diseases. Overexpression of Trx can reduce cigarette smokestimulated apoptosis through the ASK1/JNK pathway.200 Oxidation of Trx may play a
role in Alzheimer’s disease as amaloid beta causes Trx oxidation and the nuclear export
of the ASK1 downstream protein Daxx.201 Oxidation of Trx2, and subsequent release of
ASK1, by the anti-inflammatory drug troglitazone can lead to mitochondrial
permeabilization.202 The Trx/ASK1 pathway is also used in therapy modes. For example,
the chemotherapeutic cisplatin has mechanisms of action that include the activation of
ASK1/p38 through decreasing TrxR activity and enhancing Akt activation.203
Thioredoxin inhibiting protein (Txnip) is upregulated by ceramide, a tumor-suppressor
lipid that is generated by cells under stress conditions, as well as by cancer cells exposed
to genotoxic chemotherapy. This upregulation of Txnip can lead to an increase in
Trx/Txnip interactions and a decrease in Trx/ASK1 interactions, freeing ASK1 to
promote apoptosis.204

Trx also has regulatory abilities with cytochrome 450s, hypoxia-inducible factor-1 (HIF1), and Nrf-2.150 In non-small cell lung cancer, Trx is a HIF-1α stabilizer,205 and in
HT1080 cells the overexpression of Trx leads to the increase in HIF-1α when under
hypoxic conditions.206 Silencing of Trx decreases HIF-1α, as well as vascular endothelial
growth factor expression.206 On the other hand, HIF-1 accumulation is decreased by Trx2
overexpression. Trx increases and Trx2 decreases cap-dependent translation, and HIF-1
transactivation is stimulated by Trx, but decreased by Trx2. From this data, it has been
suggested that thioredoxins may contribute to the synthesis of HIF-1α.207
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Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that transcribes
genes for antioxidants, xenobiotic detoxifiers, and other cytoprotective proteins.208 Nrf2
is a transcription factor of thioredoxin that is activated in the cytoplasm by an oxidative
signal.209 Nrf-2 increase in expression is correlated with an increase in Trx.210 Nrf2 may
assist in the regulation of the entire Trx system, as cadmium-induced Nrf2 activation and
binding to antioxidant response element in the TrxR gene promoter leads to TrxR gene
expression.211 For Nrf2 to bind to the DNA it must be reduced at a critical cysteine,209
and while Nrf2 translocation is regulated by glutathione, nuclear Trx regulates the
antioxidant reporter element.212 An increase of Nrf2 in tamoxifen-resistant MCF-7 cells
has been shown and may be due either to an enhancement in the stability in the protein
with long-term exposure to tamoxifen, or to an increase in gene transcription. It has been
suggested that the Nrf2/ARE-mediated increase in antioxidant proteins such as
thioredoxin and peroxiredoxin 1 is involved in tamoxifen resistance.213 It does not appear
to have been explored, however, if such an increase in Trx results in an increase in active
Trx, as opposed to oxidized Trx, which could occur from the increase in ROS from
tamoxifen treatment.

Macrophage migration inhibitory factor (MIF) is now recognized as being part of the
thioredoxin superfamily,214 and Trx is able to suppress MIF production. 215 It has been
shown that as nuclear MIF increases, p27 levels decrease. It would seem to follow,
then, if Trx were increased, MIF levels would decrease and allow p27 levels to increase.
The association with Jab1 may also play a role in this as Jab1 is also known to interact
with MIF.216
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Thioredoxin inhibiting protein (Txnip) is also known as vitamin D3 up-regulated protein
1 (VDUP1) and Trx-binding protein-2 (TBP-2).21 As mentioned earlier, Txnip is an
antagonist of Trx, and various stressors, including ROS, regulate its expression.217 Txnip
is often decreased in tumor cells and tissues. It negatively regulates Trx, and VDUP1
(Txnip) -/- mice present with a higher susceptibility to carcinogenesis and defective
immune system.218 Txnip forms a stable complex with reduced Trx that is disulfide
linked.219 In the mouse uterus, estrogen treatment decreases Txnip expression and
increases Trx, Trx2, and TrxR expression, as evidenced by mRNA levels. 220 Txnip is
found at low levels in human cancers.21 An overexpression of Txnip leads to a decrease
in Trx activity, as well as slow growth and apoptosis susceptibility.157 For example,
colonic mucosa from ulcerative colitis and colorectal cancer specimens have significantly
decreased Txnip levels as compared to normal tissue.221

Txnip appears to be closely linked to hyperglycemia. Txnip-deficient mice that have been
fed are metabolically similar to mice that have fasted. While the thioredoxin activity of
the fed Txnip-deficient mice was similar to wild type, the deficient mice also presented
with an increase in the NADH to NAD+ ratio.222 In beta cells, glucose increases
expression of Txnip and apoptosis.223 High glucose levels also increase Txnip expression
in renal proximal tubule cells (HK-2).224 In breast cancer cells, hyperglycemia affects
Txnip levels, with tumorigenic cells expressing a low level and metastatic cells
expressing a high level. Hyperglycemia was found to increase paclitaxel cytotoxicity, and
this was also associated with Txnip expression.225 In MDA-MB-231 breast cancer cells,
hyperglycemia increases Txnip RNA within 6 hours of exposure.226
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When Txnip was explored for its metabolic effects in type 2 diabetes, patients with one
particular variant, TXNIP-T, had both higher diastolic blood pressure (5.5 mmHg) and
higher trigliceride concentrations (1.6 fold).227 In INS-1 insulinoma beta cells that
overexpressed Txnip, 90 of 98 genes that were differentially expressed were
downregulated. It is thought that Txnip is able to enhance beta-cell death and decrease
insulin secretion through its modulation of genes that are involved with cell death, cell
survival, and insulin secretion.228

There are many proteins that interact with members of the Trx family. Table 1 explores
many of these interacting proteins. From this table we can see the variety of ways in
which thioredoxin family members may play a role in cell cycle progression, as well as
how oxidation of thioredoxin can lead to a disruption in regular cell function.

TABLE 1 Intracellular Trx family interactions
Trx enhances AP-1 binding to DNA via Ref-1 (redox factor-1)
Trx inhibits PPAR
Trx inhibits Apoptosis signal-regulating kinase (ASK) 1
Trx1 suppresses MIF production
Nuclear Trx regulates the antioxidant reporter element of Nrf2
Nrf2 transcription factor may assist in the regulation of the Trx system
Nrf-2 increase in expression is correlated with an increase in Trx
Overexpression of Trx2 decreases HIF-1 accumulation
Cyanidin elevates Trx expression
H2O2 increases Trx expression
H2O2 increases Trx mRNA
UVA-irradiation increases intracellular levels of Trx
Homocysteine upregulates Trx expression
5-aminolaevulinic acid-based photodynamic therapy (ALA-PDT) increases Trx
expression
Sulforaphane induces Trx
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Cancer cells secrete Trx
Superoxide and H2O2 oxidize Trx
Paraquat and Rotenone oxidize Trx
2-[(1-methylpropyl)dithio]-1H-imidazole (PX-12) oxidizes Trx
Trx is a HIF-1a stabilizer
Overexpression of Trx leads to the increase in HIF-1a under hypoxic conditions
Silencing of Trx decreases vascular endothelial growth factor expression.
Selenium supplementation increases TrxR activity
Sulforaphane, Erucin, Iberin induce TrxR
1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)] ethane (BBSKE) inhibits TrxR
Auranofin inhibits TrxR
Green tea extracts inhibit TrxR
Cyclophosphamide inhibits TrxR
Mercury toxicity leads to the selective inhibition of TrxR
Estrogen increases Trx, Trx2, and TrxR expression
Overexpression of thioredoxin peroxidase II decreases H2O2
Txnip can interfere with Trx/ASK-1 interactions
Txnip is an antagonist of Trx
Estrogen decreases Txnip expression
Histone deacetylase inhibitors upregulate Txnip
Glucose increases expression of Txnip

Background to a new paradigm for antiestrogen resistance
Thioredoxin and cell cycle progression/arrest: As we look at the role thioredoxin may
play in antiestrogen resistance, we briefly discuss how estrogen actions are controlled by
redox regulation and other interacting proteins that can affect this change in a breast
cancer cell’s sensitivity to AE treatment and AR resistance.

Thioredoxin appears to play an important role in the redox state of the estrogen receptor.
Using the breast cancer cell line ZR-75-1, researchers have shown that when cells were
treated with H2O2, there was a decrease in the levels of pS2, a gene induced by estrogen.
When, however, cells were transfected with thioredoxin, the expression of pS2 was
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restored in the H2O2-treated cells.106 In a study regarding estrogen and congestive heart
failure, subcutaneous slow release pellets of estrogen (0.5 mg/60 day release) offered
antioxidative properties. These properties were also associated with an increase in the
expression of Trx, TrxR, and TrxR activity. In this form, estrogen also reduced ASK-1
activation, JNK activation, and p38 MAPK, which can all be related to the increase in
availability of thioredoxin. These data may show that thioredoxin could be conferring the
antioxidative properties that are being linked to estrogen.231

In another example of Trx and estrogen interactions, 17β-estradiol normalizes
thioredoxin reductase and glutathione reductase levels in rats that had been
ovariectomized. As this was not also seen when 17α-estradiol, which is non-receptor
binding, was administered, it has been suggested that glutathione and thioredoxin systems
may be stimulated by estrogen through estrogen-receptor positivity.41 Endometrial
stromal cells not only increase Trx secretions with estrogen treatment in a time-dependent
manner, but this effect has been enhanced with an estrogen and progesterone combined
treatment.144 In the interaction between estrogen and the thioredoxin system in mice, the
main component of the thioredoxin system found affected by estrogen was thioredoxininteracting protein (Txnip). While Txnip mRNA levels rise in the initial treatment of
mice with estrogen, after 2 hours both mRNA and protein amounts drop approximately
20 per cent, followed by a rise in levels of the other members of the thioredoxin family
by 2.5- to 4-fold over 24 hours. This reaction was prevented when the mice were treated
with the estrogen antagonist ICI 182780, which suggests a role for the estrogen receptor
in Txnip decrease upon estrogen treatment.220 Inhibition of TrxR reduces estrogen’s
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cytoprotection against neurodegeneration.42 When this was explored in bovine aortic
endothelial cells, it was found that 17β-estradiol increased the levels of thioredoxin,
glutaredoxin, and thioredoxin reductase. When cells were treated with tamoxifen, it
inhibited the induction of these three proteins.43 Estrogen metabolites 4-OH and 2-OH
have been found to be mediated by p450 CYP1B1 and CYP1A1 respectively. CYP1B1 is
induced by Trx in MCF-7 cells, and in MCF-7 cells that have been Trx-1 transfected,
there is a decrease in ERα expression.232

We have discussed the link between Trx family members and estrogen, and the role ROS
plays in the inhibition of Trx actions. We will now discuss other proteins that play a role
in our novel paradigm of tamoxifen resistance.

p27: p27KIP1 is a 27 kD protein found in the nucleus, where it is active and inhibits
cyclin-dependent kinases (cdks),233 most specifically by binding with the cyclin E/cdk2
or cyclin A/cdk2 complexes.234, 235 p27KIP1 (herein called p27) belongs to the CIP/KIP
(cdk inhibiting and kinase inhibiting proteins) family and suppresses the G1-to-S phase of
the cell cycle233, 236 in G0 and early G1, where it inhibits cyclin E/cdk2 through binding to
the cyclin E protein.235, 237 Highest concentrations of p27 can be found bound to the
cyclin E/cdk2 complex during cell quiescence in normal epithelial cells.238 Cyclin E,
when bound to the cyclin-dependent kinase cdk2, activates cdk2. If p27 is not available to
inhibit this complex, the activated cdk2 phosphorylates the tumor suppressing
retinoblastoma protein, which then disassociates from the E2F transcription factor,
leading to the transcription of genes that allow progression into the S phase of the cell
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cycle.235, 237 The phosphorylation of the retinoblastoma protein is necessary for the cell to
move from the G1 to the S phase of the cell cycle, and both D-type and E-type cyclins
can lead to this phosphorylation.239 Cyclins E, A, and D are involved with G1
progression, and p27 can play a dual role when interacting with these cyclins. While
unphosphorylated p27 inhibits cell cycle progression through cyclin E/cdk2 and cyclin
A/cdk2 binding,237 properly phosphorylated p27 can assist in assembling cyclin D with
cdk4 and cdk6, creating complexes that further G1 progression. Many cell lines require
high levels of p27 to stay in quiescence, and thus the down regulation of p27 is necessary
for cell cycle progression.240 There are several ways in which p27 can become
inactivated, and thus lose its inhibitory action and promote cell cycle progression.
Localization, phosphorylation, and proteolysis are three known factors affecting the
activity state of p27. The location of p27 plays an important role in the inhibition of the
cell cycle, because while it is inhibiting cell cycle progression it remains bound to the
cyclin E/cdk2 complex in the nucleus. However, upon proper phosphorylation, it moves
to the cytoplasm as the cell moves into G1, where it can either assemble cyclin D/cdk
complexes or undergo proteolysis. p27 has been found in the cytoplasm in approximately
40% of primary breast cancers, and this relocation of p27 can increase the dedifferentiation of tumors, and decrease the chances for survival.237 Phosphorylation of
p27 can change the function of the protein. Several phosphorylation sites and their
functions are currently known. Phosphorylation at threonine 157 can both impair the
nuclear import of p27 and promote the assembly of cyclin D/cdk complexes.241 Through
phosphorylation at threonine 198, p27 can help a cell survive through autophagy in
cellular metabolic stress, and can also promote cyclin D/cdk assembly, with the addition
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of tyrosine phosphorylation.242 When E2 binds to the ER, there is as activation of Src,
which can lead to phosphorylation of p27 at tyrosines 74 and 88. This encourages
phosphorylation at T187 as well as reduces the half-life of p27. Tamoxifen also interacts
with Src, furthering the role of p27 in breast cancer inhibition. When Src is inhibited, the
actions of tamoxifen are enhanced. This shows an important role for Src, and thus p27
phosphorylation, in breast cancer cell survival.243

The phosphorylation of p27 at tyrosines 74, 88, and 89 can also reduce p27’s affinity for
cdk2.238 Cyclin E-cdk2 can phosphorylate p27 at threonine 187, an action that can lead to
the marking of p27 to be recognized by its ligase (SCF-type E3), which further leads to
the ubiquitylation of p27 and its 26S proteasome-related degradation.235, 244 Serine 10
phosphorylation is necessary for p27 to be transported out of the nucleus,237 and in this
way assists with ubiquitination (and subsequent proteolysis) of p27 in late G1. In many
human cancers, activation of p27 proteolysis appears excessive, with it being seen
approximately 41-69% in breast cancer.237

Approximately 60% of primary human breast cancer and other cancers express a reduced
amount of p27 and are associated with poor patient outcome.244 Loss of p27 is also
correlated with tumor grade increase.245 Low concentrations of p27 have been found to be
associated with a 3.4-fold increased risk of death (p=0.0306), and an increase of risk of
relapse of 2.7-fold (p=0.01). Other studies have shown a decrease in overall survival
when there is a low p27 concentration and high cyclin E content (RR=2.7, p=0.01).246
Reduced levels of p27 are a poor prognostic factor in several other carcinomas as well,
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including colon, lung, prostate, esophageal, and gastric carcinomas,247 and oral dysplasias
and carcinomas.248

A key to p27 ubiquination is its nuclear export to the cytoplasm. This can be influenced
by p27 binding to CRM1.249 It has been implied that Jab1 may be a bridging protein
between p27 and CRM-1, as treatment of NIH3T3 cells with leptomycin B (a specific
CRM-1 nuclear export inhibitor) decreased p27 nuclear export by Jab1.250 It also has
been shown, however, that CRM-1 binds to p27 at its cdk2 binding site to export it from
the nucleus.251 We next explore Jab1 as part of our paradigm for tamoxifen resistance.

Jab1: Jab1 (Jun activation domain-binding protein 1) is a ~40 kD protein that was named
for its interaction with c-Jun at its activation domain. Jab1 is the 5th subunit in the COP9
signalosome, and is also known as CSN5.252 The COP9 signalosome is a known coactivator of the AP-1 transcription factor,123 and Jab1 is known to interact with at least 4
other subunits in the COP9 complex; CSNs 1, 2, 4, and 7.253 Jab1 stabilizes c-Jun or JunD
complexes at their AP-1 binding sites, which allows the specificity of the target gene
activation to be increased. When Jab1 interacts with the c-Jun protein, it enhances the
binding power of AP-1 complexes that contain c-Jun. This increases AP-1-dependent
transcription, which then leads to cell proliferation.123, 252 Nuclear receptor transcriptional
transactivation can be modulated by Jab1, as can be seen with progesterone receptors.
The addition of Jab1 can enhance the capability of the progesterone receptor to perform
hormone-dependent transactivation. This enhancing ability has also been shown with
glucocorticoid, mineralocorticoid, androgenic and estrogenic receptors, and NF-κB.254
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Nuclear receptor binding protein (NRBP) may be a negative regulator of Jab1-mediated
functions, as phosphorylation of c-Jun and AP-1 activation is inhibited by the addition of
NRBP, and thus may inhibit tumor progression.255

There is a difference in action between the smaller Jab1 complex and the larger COP9
complex. Researchers note that a loss of anchorage leads to the downregulation of the
smaller Jab1 complex, that when p27 is downregulated the smaller Jab1 complex was
upregulated, and that throughout the cell cycle the small Jab1 complex moves between
the monomeric state and the COP9 signalosome.216

One of the significant common themes with Jab1 is its numerous interactions with multiprotein complexes that appear to be connected to ubiquitin-dependent protein degradation
pathways.253 Jab1 interaction with p27 is a good example of this. It has been suggested
that Jab1 can lead to cell proliferation through the translocation of p27 from the nucleus
to cytoplasm and accelerating p27 degradation through the ubiquitin/proteosome
pathway.256 Jab1 has been negatively associated with p27 expression in a variety of
cancer cells. The expression of both Jab1 and p27 in breast carcinomas in regards to
clinical outcomes has been explored, and it has been found that in 60% of the carcinomas
studied there is a reduced or depleted existence of p27. Researchers also looked at the
possibility of using this information in a prognostic way, and saw that those patients with
tumors that were Jab1-negative did not relapse or show signs of disease progress.257
Translocation of p27 can occur due to mitogenic stimuli,233 and Jab1 has been implicated
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as a major cause for the translocation of p27 from the nucleus to the cytoplasm. When
p27 and Jab1 are cotransfected, there is acceleration in p27 proteolysis.249

Vitamin D3 upregulated protein 1 (Txnip) is also a Jab1 inhibitor that blocks the ability of
Jab1 to move p27 from the nucleus to the cytoplasm, as well as blocking its co-activation
of AP-1.258 The proteolysis of p27 is thought to be mediated by not just Jab1, but by the
COP9 signalosome as well. There are at least three other parts of COP9 (namely CSN6,
CSN7, and CSN8) which also can lead to the downregulation of p27 when they are
expressed ectopically. 259

In a study of levels of p27 in benign and malignant lesions in 94 randomly selected cases
at the University of Texas MD Anderson Cancer Center, fourteen out of seventeen
standard nevi cases showed a strong expression of p27 in over 75% of the cells. Out of 22
melanoma cases, only 3 showed expression of p27. And out of 30 cases of metastatic
melanoma, only 4 were p27 positive. The expression of Jab1 in these same samples was
also investigated. Jab1 was expressed in 14 out of 17 cases of standard nevi, and in 18 out
of 19 dysplastic nevi, with 11 of those strongly Jab1-positive. While only few of the
primary melanoma cases were p27 positive, approximately 77% of them were Jab1
positive. Metastatic melanomas were Jab1 positive in 53% of the cases. This pattern was
seen across different histologic types of melanoma. 233 This theme of high Jab1 and low
p27 in cancer is seen in several studies.257, 260-262 In breast cancer, there is an increase in
Jab1 in adjacent normal cells as compared to normal breast cancer cells.263 Interestingly,
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there is initial evidence that cytoplasmic p27 is present in invasive tumors, yet not in noninvasive tumors, presenting the possibility of a role for cytoplasmic p27 in metastasis.264

It has been shown that Jab1 and ERα interact (either directly or indirectly) through a
finding that Jab1 comimmunoprecipitates with ERα. Also, an increase in Jab1 levels is
associated with hormone-induced ERα degradation. Curcumin, which inhibits CSNassociated kinase activity and prevents the degradation of ERα, increases the amount of
coimmunoprecipitated Jab1 and ERα, as well as blocked ERα phosphorylations and
degradations that are ligand dependent.265

It has been presented that Jab1 location is well regulated within the cell, and is present
mostly in the nucleus, though there are small amounts in the cytoplasm. The Jab1 signal
is also very strong in adult tissues that are terminally differentiated.266

Thioredoxin and its proposed role in antiestrogen resistance: With the oxidation that
is produced by both estrogen and tamoxifen, the redox nature of proteins cannot be
ignored as a possible player in tamoxifen resistance. Tamoxifen-resistant breast cancer
tumors show decreased glutathione levels, and it is suggested that the increase in
tamoxifen-induced oxidative stress and decreased glutathione levels activate JNK and
increase AP-1 actions, leading to growth in the presence of tamoxifen.68 As mentioned
earlier, tamoxifen inhibits estrogen-induced thioredoxin, glutaredoxin, and thioredoxin
reductase.43 Also, when cells proliferate in a manner that forms cellular masses, cells are
deprived of oxygen and nutrients, which leads to cellular adaptations that allow the
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cancer cell to survive (i.e. the suppression of apoptosis).267 Trx reductase has a variant,
labeled TrxR1b, which is thought to influence the assembly of estrogen receptor
coactivator complex. As such, it may modulate estrogen signaling.268 When doxorubicinresistant small cell carcinoma lung cells are treated with selenium, the result is caspase-3independent apoptosis. While TrxR levels and activity increases with this treatment, the
amount of truncated Trx does not change.269 These cancer studies on Trx do not observe
the oxidative state of the Trx that is being measured, and results such as these could be
due to TrxR reducing Trx and restoring its activity.

As mentioned earlier, most studies on Trx and resistance focus on Trx’s anti-apoptotic
role. Response to docetaxel, a potent anti-cancer drug used with breast cancer patients,
has been linked to thioredoxin. In a study on Docetaxel and the gene expression that may
predict resistance to the drug, thioredoxin was one of several proteins that, when
overexpressed, meant there was a good chance the person would not respond to the
anticancer drug.270 Trx expression is correlated with platinum-based drug resistance.271
High levels of thioredoxin have been associated with resistance to cisdiamminedichloroplatinum (II) (cisplatin), mitomycin C, doxorubicin, and etoposide. To
test this association with docetaxel, thioredoxin expression was related to its reaction to
estrogen receptor positivity. It was found that patients with ER negative tumors low in
thioredoxin showed the highest response to docetaxel treatment (42.3%) and the lowest
response (0%) was in patients who had high thioredoxin levels and were estrogen
receptor positive. When patients were treated with thioredoxin prior to docetaxel therapy,
thioredoxin levels rose upon treatment with the drug. While levels of thioredoxin
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increased equally across cell samples, it was noted that it was the high level of
thioredoxin present before docetaxel treatment that confers resistance, not the increase at
the time of treatment.272 It is thought that thioredoxin may contribute to other anti-cancer
drug resistances. When a thioredoxin antisense plasmid was transfected into cisplatinresistant T-cell leukemia cells, sensitivity to cisplatin, as well as several other anticancer
drugs, was restored.21 When selenium treatment was added to doxorubicin-resistant cells,
caspase-3-independent apoptosis occurred. There was also an increase in TrxR protein
levels and activity, and truncated Trx increased.

While these studies show the role of Trx as an agonist for chemotherapeutic drug
resistance, we suggest that the role Trx plays in other protein actions (outside of reducing
the effects of ROS) is affected by the overoxidation of Trx and can play a role in
antiestrogen resistance (see Figure 4-LR). We suggest that the oxidative state of cells
treated with antiestrogens will add a constant state of oxidative stress, and will create an
adaptation in the cellular mechanism that leads to resistance to antiestrogens, namely
through an oxidation of thioredoxin.

Jab1 and a possible interaction with thioredoxin: When hepatopoietin (HPO) loses its
sulfhydryl oxidase abilities at its cysteine residues, it is no longer able to affect AP-1
activation due to its lack of ability to interact with Jab1. This does not affect HPOs ability
to promote growth via the MAPK pathway.273 However, this suggests that the sulfhydryl
ability of an interacting protein will affect its interaction with Jab1, as may be the case
with thioredoxin. Trx has been found to compete with p27 for binding with Jab1 in
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HEK293T (human embryonic kidney) cells, and through this, negatively regulate p27
degradation. The possibility that Trx could affect Jab1/p27 binding in these cells was
explored, and it was found that the addition of Trx to cells altered the direction of Jab1induced p27 level decrease. It was also found that the addition of Trx did not increase
levels of p27 when Jab1 was not overexpressed. This led to a hypothesis that Trx
competes with p27 for binding with Jab1. The researchers showed that Trx specifically
interacts with the C-terminal of Jab1, while p27 is known to interact with the N-terminal.
The hypothesis was that when Trx binds with Jab1, it produces a conformational change
that inhibits the binding affinity for p27. This decrease in binding affinity could then
allow p27 to continue to bind to the cyclin E/cdk2 complex, and inhibit cell proliferation.
Another Jab1 effect that was inhibited by Trx binding was AP-1 activation. When Jab1
levels were increased, Trx was found to decrease AP-1 activity. Increased Jab1 levels
have been found in certain cancers of the pituitary, ovary and breast and in certain
lymphomas. Because of the increased Jab1 expression in these tumors, Trx could play an
important role in decreasing AP-1 activity, but also in keeping Jab1 from removing p27
from the nucleus.123 Figure 5-LR shows this interaction and a possible role for Trx in
keeping Jab1 from moving p27 out of the nucleus. The possible oxidation and
inactivation of Trx through tamoxifen treatment can lead to an increase in p27 removal
from the nucleus by Jab1.

PTPs and thioredoxin: Particularly susceptible to oxidation are protein tyrosine
phosphatases (PTPs), including PTEN, PTP1B, cdc25, and low molecular weight PTP.87,
116

Several PTPs have been show to correlate with p27 levels. A downstream molecule in
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the phosphoinositol 3’ kinase (PI3K) pathway, protein kinase B (Akt), can phosphorylate
p27 at T157 and inhibit its import to the nucleus. This prohibits p27 from inhibiting cell
proliferation.274 When the PI3K pathway has been activated, as it is in human cancers, it
has been found that p27 concentrations decrease. This effect is reversed by the PI3K
inhibitor LY294002, a “kinase-dead” PKB/Akt, or the PI3K phosphatase PTEN. When
PI3K activation is opposed by PTEN in specific cell lines, p27 concentrations increase. It
has been suggested that PTEN may work in this way through repressing SKP-2, a
component of the SCFSKP2 ubiquitin ligase.237 Overexpression of the PTEN gene
increases p27 levels, decreases cyclin D1 levels, inhibits the phosphorylation of Akt, and
through these mechanisms inhibits cell growth in MCF-7 cells.275 In human mammary
epithelial cells (HMEC), activation of the PI3K pathway is necessary for the cell to move
from G1 to S because of its activation of the cyclin E/cdk2 complex.240 The CDC25A
PTP has been linked to cdk2. CDC25 is a dual specificity PTP that dephosphorylates
cyclin E-cdk2 inhibitory phosphorylation sites. In this way, CDC25A controls S phase
entry and progression. PTP1B has been associated with the Src family kinases, as well as
with other pathways.276, 277 Src has two phosphorylation sites that can be affected by
phosphatases. While one is an inhibiting site, the other is an activation site that is
autophosphorylated. PTP-BL dephosphorylates Src at this activation site, keeping Src
inactivated.278 Src binding to PTP1B is proline residue dependent.279 When PTP1B is
downregulated, a decrease in ERK1/2 phosphorylation has been shown, as well as a
dephosphorylation of Src at the inactivation site.277 When HEK293 cells are transfected
with both Src and TRPV6, a cation channel, the tyrosine phosphorylation that Src
imposed on TRPV6 is dephosphorylated by PTP1B.280
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These same PTPs are also reduced by Trx. PTEN can be oxidized by H2O2, and then
reduced by Trx.281 CDC25 PTPs are known to react directly with ROS due to their
catalytic cysteine residue. This reaction causes an inactivation in the CDC25 enzyme
through creating a disulphide that can be reversed by thioredoxin.282 283 While no data is
available for the actions Trx may have on PTP-BL, it is known that PTP-BL contains two
cysteine residues that appear to regulate binding, and that this binding capacity is lost
when a reducing treatment is added.284 PTP1B has been linked with thioredoxin through a
murine study using selenium supplementation. Rats that were fed 75 or 150 μg of
selenium/kg showed an increase in thioredoxin reductase, as well as other selenoproteins,
and a decrease in PTP1B glutathionylation (which inhibits PTP activity).285

It is possible that the oxidation of PTPs via the oxidative stress of tamoxifen treatment
can play an important role in tamoxifen resistance through lack of interaction with
kinases that phosphorylate p27. In the suggested case of an increase oxidized state in the
cell by chronic tamoxifen treatment, oxidized Trx is unable to reduce p27-affecting PTPs,
which could play a role in the continued growth of cancer cells in the presence of
tamoxifen treatment.

6. Summary
The mechanisms of antiestrogen resistance are complex. Here we have presented the data
involving Trx and show different ways Trx may have a role in antiestrogen resistance in
breast cancer. As cells are chronically exposed to ROS from long-term tamoxifen
treatment, they can adapt to this increasing level of ROS and oxidative stress. This can
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lead to oxidation of certain cellular antioxidant systems, such as thioredoxin, causing
them to become inactive. The inactivation of the thioredoxin antioxidant family can then
affect other proteins such as PTPs or Jab1, or lead to the continued activation of cell
signaling pathways such as MAPKs, leading to the activation of transcription factors such
as AP-1 or NF-κB and subsequent cell proliferation. It is in this way that we propose that
ROS and the thioredoxin family may play a role in tamoxifen resistance.
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Figures
Figure 1 –LR

Estrogen actions in breast cancer. Most well characterized is the genomic action of
estrogen binding to the ER, and this complex binding to EREs in the DNA. Non-genomic
actions include activation of the PI3K and MAPK pathways. More recently, cellsignaling activation through ROS formation has been explored.23, 28,29,126,286,287
Figure 2-LR
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Sources of oxidants and actions of antioxidants. Schematic of major sources of ROS
and antioxidants that counteract the oxidative effects of this ROS.
Figure 3-LR

Cellular dose/response to oxidants. While high doses of ROS can lead to apoptosis, and
low levels can lead to cell growth, chronic exposure to antiestrogens can lead to an
adaptation of the cell and subsequent AE resistance.
Figure 4-LR

Thioredoxin oxidation and reduction. After oxidation, thioredoxin becomes more
susceptible to overoxidation by H2O2 until it become irreversibly inactive. The increase
in ROS from tamoxifen treatment can lead to the oxidation and overoxidation of
thioredoxin, and perhaps plays a role in antiestrogen resistance.
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Figure 5-LR

Proposed role of thioredoxin in AE resistance. We propose a Trx/Jab1 interaction that
mimics the Trx/Ask1 interaction. Oxidation (inactivation) of thioredoxin from AEgenerated ROS leads to a release of Jab1. Jab1 is then free to bind to p27, carrying it
out of the nucleus. With p27 gone, the Cyclin E/cdk2 complex is free to forward cell
cycle progression.
III

INCREASING THIOREDOXIN REDUCTASE EXPRESSION OR

REDUCING JAB1 EXPRESSION REDUCES CELL PROLIFERATION IN
TAMOXIFEN-TREATED LCC2 CELLS
Abstract
Antiestrogen resistance is a major problem in breast cancer treatment. While the reactive
oxygen species that are produced by selective estrogen receptor modulators such as
tamoxifen are not thought to play a major role in treatment, it may have a role in the
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development of resistance. For this study we looked at the role of thioredoxin and its
ability to alter the oxidative state of tamoxifen-resistant (LCC2) cells. We also explored
the Jab1/thioredoxin pathway as a way thioredoxin may alter the effects of resistance on
the cell cycle inhibitor p27. We show that overexpressing thioredoxin reductase or
underexpressing Jab1 inhibits growth of tamoxifen-resistant cells upon tamoxifen
treatment. We also show that p27 phosphorylation is altered when thioredoxin reductase
or Jab1 levels are altered. This data implies a role for antioxidants in reversing tamoxifen
resistance. Through altering p27 phosphorylation, changing the redox nature of tamoxifen
resistant cells may not only reverse but also may prevent tamoxifen resistance.

Introduction
A major problem with the use of antiestrogens (AE) is the prevalence of resistance, either
at the outset of treatment or after continued use, and underlying mechanisms of this
resistance remain unclear. Selective estrogen receptor modulator (SERM) antiestrogens
are capable of producing ROS through their metabolic activation. It is possible that
SERMs may play a role in estrogen receptor (ER) positive breast cancer growth arrest by
a mechanism involving ROS accumulation. Breast cancer receiving long-term
antiestrogen treatment appears to adapt to this increased, persistent level of ROS, leading
to the disruption of reversible redox signaling that involves redox-sensitive phosphatases
and kinases, such as ERK and Akt. This has downstream consequences for apoptosis, cell
cycle progression, and cell metabolism.1, 2
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The inactivation of the thioredoxin antioxidant family can disrupt reversible redox
signaling pathways and cause the cell to become unresponsive to certain stimuli, or lead
to the continued activation of cell signaling pathways such as MAPKs, and further the
activation of transcription factors and subsequent cell proliferation.3 It may also play a
role in making Jab1 protein available to move the cell-cycle inhibitor p27 from the
nucleus and freeing the cyclin E / cdk2 complex to forward cell progression. Thioredoxin
(Trx) has been found to compete with p27 for binding with Jab1 in HEK293T (human
embryonic kidney) cells, and, through this, negatively regulate p27 degradation.4

There is very little research in the area of reactive oxygen species as a mechanism for
tamoxifen resistance. One study has looked at glutathione as an antioxidant that can
affect the oxidation of the MKP3 phosphatase. There appear to be no studies exploring
the role of thioredoxin as an inhibitor of antiestrogen resistance. There also are no studies
regarding the role of Jab1 in AE resistance, however, it has been shown that there needs
to be a certain level of p27 in breast cancer cells for the cells to respond to tamoxifen, and
that increasing MAPK pathway activation increases p27 phosphorylation and reduces
levels of p27, leading to tamoxifen resistance.5

Thioredoxin and thioredoxin reductase (TrxR) are considered prime targets for resistance
to chemotherapeutic drugs that utilize high levels of ROS to kill breast cancer cells, such
as docetaxel, a potent anti-cancer drug.6 However, with drugs that do not utilize ROS as
their main mechanism, such as tamoxifen, chronic exposure to the lower levels of ROS
produced have not been explored as part of the mechanisms of action. With the exception
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of the previously mentioned MKP3 study, the alteration of cellular ROS has not been
explored as a pathway to reversing/preventing tamoxifen resistance.

We suggest that chronic tamoxifen usage increases ROS and inactivates the antioxidant
Trx family through oxidation. This oxidation can affect several signaling pathways and
lead to cell cycle progression in the presence of tamoxifen treatment. In this study we
overexpressed thioredoxin reductase and underexpressed Jab1 proteins to explore the role
of each in tamoxifen resistance. Our data indicate there is a role for TrxR overexpression
or Jab1underexpression in reversing or preventing tamoxifen resistance through alteration
of p27 phosphorylation.

Materials and methods
Cell lines, cultures, and treatments: The tamoxifen-resistant/fulvestrant-sensitive human
breast adenocarcinoma MCF-7-variant LCC2 cell line was propagated in phenol red-free
Dulbecco's Modified Eagle Medium F12 (DMEM/F12) with L-Glutamine and 15mM
HEPES (Invitrogen, Grand Island, NY; Mediatech, Manassas, VA) containing 5% (v/v)
fetal bovine serum (Invitrogen), 100 u/mL penicillin G sodium, and 100 ug/mL
streptomycin sulfate (Invitrogen) at 37 °C in 5% CO2 atmosphere. For experimental
purposes, cells were seeded in 5% FBS DMEM/F12 medium and allowed to adhere
overnight. Culture medium was replaced with DMEM/F12 with 5% charcoal/dextrantreated FBS (Invitrogen), and allowed to grow for 48 h, followed by treatments (0.1%
DMSO, 1 μM tamoxifen, 1 μM fulvestrant [Sigma, St. Louis, MO]) as described in the
figure legends. For cells with erucin treatment, 10 μM erucin (LKT Laboratories, St.
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Paul, MN) was added with the DMEM/F12 with charcoal/dextran-treated FBS for the
initial 48 hours in order to overexpress thioredoxin reductase 1 (TrxR1). Media was then
removed from erucin-treated cells, fresh media was added, and treatments administered.

Transfection procedures: pRS shRNA vector without shRNA cassette insert, pRS HuSH
29mer shRNA constructs against COPS5 (Jab1), and pCMV6-XL4 carrying the fulllength human TrxR2 cDNA (OriGene Technologies, Rockville, MD, USA) were purified
using MAX Efficiency® DH5α™ Competent Cells (Invitrogen) and plasmid was
extracted using phenol extraction and ethanol precipitation. For transfection, cells were
seeded in 6-well plates at 70%. After overnight incubation, transfection was performed
using Fugene (1:3) and left to incubate overnight in Optimem (Invitrogen) or DMEM/F12
with no serum or antibiotics. The next day media was changed to growth media and cells
were allowed to recuperate overnight. Cells were seeded the next day. HuSH 29-mer noneffective (scrambled) pRS vector (Origene) was tested and showed similar actions to the
empty plasmid vector (data not shown).

Antibodies: All antibodies used were purchased from Santa Cruz (Santa Cruz, CA),
except the following: GAPDH (Sigma), β-actin (Sigma), and p27 phosphorylated at T157
(Abcam, Cambridge, MA).

Soft agar colony formation assay: Cells were seeded at a concentration of 500 cells/well
in 0.25% agar on a 0.5% agar base using 5% FBS in 48-well plates. Cells were fed 2
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times per week with treatments as described in figure legends, and colonies were counted
on days 16 and 18. Each assay was repeated three times with triplicate treatments.

BrdU cell proliferation assay: Cells were grown (2500 cells/well) in 96-well plates in
DMEM/F12 with 5% charcoal/dextran-treated FBS for 48 h (certain wells also including
10 μM erucin), followed by treatments in DMEM/F12 with charcoal/dextran-treated FBS
as described in the figure legends for 48 h. A colorimetric BrdU cell proliferation assay
was performed according to the manufacturer’s instructions (Roche, Indianapolis, IN).
After incubation with treatments, cells were labeled for 24 hours at 37° C in 5% CO2.
After 30 minutes of fixation and denaturing (FixDenat), cells were incubated with antiBrdU-peroxidase antibody (1:1000) for 90 minutes. Cells were washed three times with
PBS, and the final substrate was added. Sample measurements were taken with Synergy
HT (BioTek, Winooski, VT) plate reader at 370 nm (reference λ at 492 nm) at time points
from 5-30 minutes at 5-minute intervals.

Redox Western: The procedure for redox western for thioredoxin has been described in
detail.7 Briefly, LCC2 cells were seeded at either 400,000 / well (6 well plate) or 1 x
106/plate (100 mm plates). After overnight incubation, media with charcoal/dextran
treated FBS was added to all cells, with 10 μM erucin added to specified wells/plates.
After 48 hours, cells were treated as noted for 30 minutes. After washing twice with cold
PBS, cells were scraped into 1.5 mL tubes with G lysis buffer with 50 mM iodoacetic
acid. Samples were incubated for 30 minutes at 37°. Lysate was sonicated briefly, then
centrifuged for 3 minutes at 2000 x g at room temperature. Lysate was transferred to new
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tubes, and a BCA assay was performed to quantitate proteins. 50 μg was loaded in a
native gel (15%) under non-reducing conditions and run for 90 minutes at 150V in native
running buffer. Proteins were transferred to PVDF (GE Healthcare), blocked with 5%
BSA, and incubated in anti-Trx antibody overnight. An SDS-PAGE (12%) was also run
with the same lysate for loading control GAPDH or B-actin. Blots were developed using
either a film developer (Konica Minolta) or VersaDoc imaging system using
QuantityOne software (BioRad).

Redox potential (Eh) of Trx1 was calculated using the Nernst equation through the use of
the reduced and oxidized bands of thioredoxin. The equation Eh (mV, redox potential) =
Eo (midpoint potential) + (RT/nF) ln(Trx1Ox /Trx1Red) was used, where Eo = -240 mV
for Trx1 at pH 7.0 and 25°C, 30=ln and RT/nF. This equation was calculated previously
by Go and Jones by using values [R, universal gas constant; T, absolute temperature; n,
number of electrons; F, Faraday constant]). The ratio of oxidized and reduced Trx1 (Trx1
Ox/Trx1 Red) band intensities was taken for each sample and used to calculate
ln(Trx1Ox /Trx1Red). Thus, the final equation (as calculated by Go and Jones, 2009)
reduces to Eh, Trx1 = −240 mV + 30 × ln(ratio of Trx1Ox and Trx1Red).
Immunoblot: Cells were seeded in 100mm plates at 1 x 106 cells in DMEM/F12 with 5%
charcoal/dextran-treated FBS and allowed to grow for 48 hours. Cells were then treated
with DMSO and tamoxifen for 48 hrs. Cells were rinsed with cold PBS, lysed (20mM
HEPES (pH 7.2), 50 mM NaCl, 0.5% Triton X-100, 0.1mM Na3VO4, 1mM NaF, 1x
complete protease inhibitor (Roche)), and proteins isolated. Quantification of proteins
was performed using the Pierce BCA Protein Assay Kit (Pierce, Rockford, IL), and lysate
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was boiled for 5 minutes at 95-100° C. Acrylamide gel (12%) was loaded with 100 μg
protein and run for 2.5 h at 150 volts. Proteins were transferred to PVDF and blots were
blocked with either 5% milk or blocking buffer for phosphorylated proteins (1% milk,
1% BSA, 50 mM NaF) in TBS-T. Blots were then incubated with anti-p27, anti-p27
(T157), and anti-p27 (T187) (Santa Cruz, US) antibodies overnight. Secondary antibodies
were added for one hour, and blots were imaged using either a film developer (Konica
Minolta) or VersaDoc imaging system using QuantityOne software (BioRad).

Co-immunoprecipitation: Cells were seeded in 100mm plates at 1 x 106 cells in
DMEM/F12 with 5 % charcoal/dextran-treated FBS and allowed to grow for 48 h. Cells
were then treated with DMSO and tamoxifen for 48 h. Cells were rinsed with cold PBS,
lysed (NP-40 buffer, 1mM NaF, 1x complete protease inhibitor (Roche)), and proteins
isolated. Quantification of proteins was performed using the Pierce BCA kit. 1000 μg
lysate was precleared with 30 uL Protein A Agarose (Invitrogen) for 30 minutes. Lysate
was separated from agarose beads, and incubated overnight with appropriate antibody (2
ug/mL). Lysates were then incubated for 90 minutes with 50 uL Agarose A slurry,
centrifuged, then supernatant removed. Beads were washed 3 times, and then 60 uL 2.5x
loading buffer was added. Lysate was boiled for 10 minutes at 95-100° C, 30 uL was
loaded in each of 2 acrylamide gels (12 and 15%), and run for 2.5 h at 150 volts. Proteins
were transferred to PVDF and blots were blocked with 5% milk in TBS-T or 5% BSA in
TBS-T (Trx). Blots were then incubated with anti-Jab1, anti-p27, or anti-Trx) antibodies
overnight. After washing, secondary antibodies were added (Santa Cruz) for 1 hour.
Images were captured using either Kodak Film or Versadoc digital imaging.
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Results
Upregulation of TrxR through Erucin treatment decreases proliferation and
tumorigenicity of tamoxifen treated tamoxifen-resistant breast cancer cells
If indeed thioredoxin oxidation is playing a role in tamoxifen resistance, we would expect
an increase in thioredoxin reductase (and the subsequent reduction of oxidized
thioredoxin) to decrease tamoxifen-resistant cell proliferation after tamoxifen treatment.
We first wanted to check the validity of this hypothesis on tamoxifen-resistant cells, and
performed a soft agar anchorage-independence assay. Anchorage-independence is a
hallmark of tumor growth, so we used this assay to see if the overexpression of
thioredoxin reductase 1 or 2 would create an atmosphere of tamoxifen sensitivity. We
transfected LCC2 cells to overexpress TrxR2 or co-treated LCC2 cells with erucin to
increase TrxR1. Cells were treated for over 2 weeks, and colonies counted on days 16
and 18. Figure 1 shows the outcome of this experiment as representative pictures (A, B,
C) and graphic representation of colony counts (D, E, F). We found that the
overexpression of TrxR1 and TrxR2 each significantly decreased the number of colonies
that formed after tamoxifen treatments.

Jab1 aids in removing p27 from its inhibitory position in the nucleus. We would expect
an underexpression of Jab1 would increase available p27 and lead to the inhibition of
tumor growth in tamoxifen treated resistance cells. We found that indeed the
underexpression of Jab1 through plasmid transfection also leads to significantly
decreased colony formation.
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We also looked at the DNA synthesis (cell proliferation) of these cells through the use of
the BrdU incorporation assay. After incubating our cells with media with
charcoal/dextran treated FBS, we treated the cells as noted for another 48 hours. We then
labeled the cells for 24 hours with BrdU, and performed the BrdU assay (Roche). The
overexpression of TrxR2 (Figure 2A), treatment of cells with erucin (overexpression of
TrxR1, Figure 2B), and the underexpression of Jab1 (Figure 2C) show significant (p <
0.05) decreases in DNA synthesis in LCC2 cells.

Upregulation of TrxR and TrxR2 through isothiocyanate treatment and plasmid
overexpression increases Trx and Trx2 expression in LCC2 cells
It has been seen in HepG2 and undifferentiated Caco-2 cells that an increase in TrxR
expression leads to an increase in expression of Trx,8 and the dietary isothiocyanates
sulforaphane, erucin, and iberin have been found to induce thioredoxin reductase in
MCF-7 cells.9 Our hypothesis is based on an overexpression of thioredoxin and/or
thioredoxin 2, and so to confirm this increase in protein expression in tamoxifen-resistant
LCC2 cells and to look at the expression of Trx2 after TrxR2 overexpression we
performed a western blot. Figure 3A shows plasmid overexpression of TrxR2 leads to an
increase in Trx2. Figure 3B shows the overexpression of thioredoxin reductase through
the use of the isothiocyanate sulforaphane, and the subsequent increase in Trx.

It is not only necessary to have more thioredoxin, but to also have more reduced
thioredoxin to understand the validity of our hypothesis. As such, we also explored if the
overexpression of thioredoxin reductase 1 and 2 led to a decrease in oxidized thioredoxin.
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Tamoxifen increases ROS in LCC2 cells, and leads to an increase in oxidized
thioredoxin in MCF-7 cells
Tamoxifen has been shown to increase ROS in cells as estrogen does. We have
previously shown that estrogen increases the oxidation of thioredoxin in MCF-7 cells.
We wanted to explore the effect of tamoxifen on thioredoxin oxidation in breast cancer
cells. Figure 4A shows that overexpression of TrxR2 increases levels of reduced
thioredoxin, as does erucin treatment (Figure 4B). These data show that the reduction of
oxidized thioredoxin occurs with the overexpression of TrxR2.

Isothiocyanates are able to oxidize TrxR and glutathione reductase.10 Here we see that
while the use of the isothiocyanate erucin increases levels of oxidized Trx, it also
significantly increases the amount in reduced (and thus active) Trx (Figure 4B). Figure
4C shows the redox potential as computed using the Nernst equation as noted in the
Materials and Methods section. While the use of isothiocyanates decreases the redox
potential due to the ratio of oxidized to reduced thioredoxin, the goal of this experiment
was to increase the amount of reduced thioredoxin available in the cell, and this was
achieved with isothiocyanate use.

We hypothesize that the oxidation and subsequent inactivation of thioredoxin may lead to
cell cycle signaling that promotes tamoxifen resistance. If thioredoxin is not reducing
other proteins, these proteins may be “switched on” or “switched off” and can cause cell
proliferation even when treated with tamoxifen. When thioredoxin is oxidized, it may not
be able to bind to the Jab1 protein, as it has been shown to do.4 This would leave Jab1
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free to bind to bind to p27, and carry it out of the nucleus, inhibiting p27 from controlling
cell growth.

Increased TrxR 1 and 2 increases Jab1/Trx binding
In a variety of cancer cells, Jab1 has been negatively associated with p27 expression.11
Jab1 has been implicated as a major cause of the translocation of p27 from the nucleus to
the cytoplasm.12 Jab1 is thought to play a role in accelerating p27 degradation through the
ubiquitin/proteosome pathway. Alternatively, Trx has been found to compete with p27
for binding with Jab1 in HEK293T (human embryonic kidney) cells, and, through this,
negatively regulate p27 degradation.4 Because of this finding, we wanted to explore the
possibility that Trx may bind with Jab1 in breast cancer cells, and to see if altering Trx
oxidative state would also alter Jab1/p27 binding. We performed a coimmunoprecipitation, pulling down the Jab1 protein and probing it for Trx and for p27.
We treated LCC2 cells as before, then incubated 1mg of protein with 2 μg Jab1 antibody
overnight and followed the protocol as noted in Materials and Methods. Figures 5A
and 5B show binding between Jab1 and Trx1, and figures 5C and 5D show binding
between Jab1 and p27 after overexpression of TrxR 1 and 2. When cells are pretreated
with isothiocyanates, an increase in binding of Jab1 and Trx occurs after treatment
with tamoxifen.

We also looked at Jab1 binding with p27, as we would expect to see Jab1/p27 binding
decrease as Jab1/Trx binding increases. While we saw a drop in Jab1/p27 binding with
the use of isothiocyanates, we did not see a significant decrease in Jab1/p27 binding as
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we expected when tamoxifen treatment was added. Thus we do not feel the binding of
p27 to Jab1 is competitive with binding of Trx to Jab1. This is the first time, however,
that Trx binding to Jab1 is shown in breast cancer cells

TrxR1 and 2 overexpression and Jab1 underexpression decrease p27
phosphorylation at T187. Increased TrxR 1 but not TrxR2 or decreased Jab1
decrease p27 phosphorylation at T157
p27 is a known cdk2 inhibitor. When p27 is phosphorylated and disconnects from cdk2,
cdk2 is free to phosphorylate retinoblastoma, which can then activate the E2F gene and
lead to cell proliferation.13, 14 We explored the phosphorylation of p27 at the T187 and
T157 sites. The T187 site is phosphorylated by cdk2 once other sources (Src)
phosphorylate p27 at T74 and T88.15 T77 and T88 phosphorylation weaken the p27/cdk2
bond, and encourage T187 phosphorylation. Once p27 is phosphorylated at these sites, it
becomes unbound from cdk2, and can be ubiquinated and subsequently degraded by the
26S proteosome.13, 16 We hypothesize that it is at this point Jab1 can bind to p27 and aid
in p27 degradation. We found that p27 is phosphorylated at 187 in LCC2 cells, but when
TrxR 1 and 2 are overexpressed or Jab1 is underexpressed, T187 phosphorylation
decreases. (Figures 6A and 6B)

The T157 phosphorylation site prohibits p27 translocation into the nucleus. As such, p27
is not available for cdk2/cyclin E binding, and cannot perform its inhibitory role. It also is
available for and promotes cyclin D1/cdk4 assembly, which forwards cell cycle
progression.17 Here we show that overexpression of thioredoxin reductase through
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treatment of cells with erucin decreases phosphorylation of p27 at T157. This decrease is
not seen when thioredoxin reductase 2 is overexpressed or Jab1 is underexpressed.
(Figures 6A and 6B)

Discussion
As mentioned earlier, most studies on Trx and resistance to breast cancer treatment focus
on Trx’s anti-apoptotic role in high ROS-producing chemotherapies. For example,
response to docetaxel, a potent anti-cancer drug used with breast cancer patients, is linked
to thioredoxin,6 and Trx expression is correlated with platinum-based drug resistance.18

While these studies show the role of Trx as an agonist for chemotherapeutic drug
resistance, we suggest that the role Trx plays in tamoxifen-treated breast cancer is
affected by the overoxidation of Trx by the chronic low to medium levels of tamoxifeninduced ROS, and that this can play a role in anti-estrogen resistance. We suggest that the
oxidative state of cells treated with anti-estrogens will add a constant state of oxidative
stress, and will create an adaptation in the cellular mechanism that leads to resistance to
antiestrogens, namely through an oxidation of thioredoxin.

We also suggest that altering Trx oxidation may alter tamoxifen-resistant cells’ reactions
to tamoxifen, and lead to a more sensitive cell. We found that reducing Trx through an
increase in TrxR did lead to higher levels of growth arrest and fewer tumor formations
(soft agar) in tamoxifen-treated cells.
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Tamoxifen is known to lead to an increase in ROS.19 Here we show that
overexpression of TrxR in tamoxifen treated resistant cells can reduce the amount of
oxidized thioredoxin.

The role of Jab1 in tamoxifen resistance has not been explored. While Jab1 has been
shown to bind to both p27 and Trx in HEK cells,4 this association has not been shown
elsewhere. Here we show that altering the redox state of Trx leads to Jab1/Trx binding
during tamoxifen treatment. We were unable to show a decrease in Jab1/p27 binding in
these experiments.

The function of p27 is also important when looking at tamoxifen resistance. While we
show that p27 levels rise when TrxR is overexpressed, more importantly we also show
decreased levels of phosphorylated p27 at T157 and T187. This implies that the increased
p27 may be able to function properly in its cell cycle inhibitory role. In total, our results
show a possible role for thioredoxin and for Jab1 in the reversal of tamoxifen resistance.
When Trx is reduced through overexpression of TrxR, or when Jab1 levels are decreased,
we show changes in tamoxifen-resistant LCC2 breast cancer cells that imply a shift of the
cell towards tamoxifen sensitivity.
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Figure 1-LCC2
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D

Upregulation of cellular and mitochondrial thioredoxin reductase reduced the
formation of anchorage–independent colonies in tamoxifen–resistant cells. Wild type
and cells overexpressing TrxR 1 and 2 were treated with either 0.1% DMSO or 1 μM
tamoxifen and 1 μM fulvestrant (positive control) in soft agar for over 14 days. (A)
Tamoxifen-resistant LCC2 cells were transfected with pCMV6-XL4 plasmid to
overexpress mitochondrial thioredoxin reductase 2. Representative pictures of colonies
with transfections and treatments as noted. (B) LCC2 cells were treated with 10 μM
Erucin as well as other treatments as noted. (D & E) Graphic representation of colony
counts with treatments as noted. Data shown are representative of minimum three
independent experiments and are presented as number of colonies +/- SD. Values that are
significantly different from empty vector control (TrxR2 overexpression) or DMSO
(erucin treatment) are marked with an asterisk (*), and those significantly different from
tamoxifen treatment are marked with two asterisks (**).
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Downregulation of Jab1 reduced the formation of anchorage–independent colonies
in tamoxifen-treated tamoxifen-resistant LCC2 cells. Wild type LCC2 cells and LCC2
cells underexpressing Jab1 were treated with either 0.1% DMSO or 1 μM tamoxifen in
soft agar for over 14 days. (C) LCC2 cells were transfected with HuSH purified pRS
plasmid to underexpress Jab1. Representative pictures of colonies with transfections and
treatments as noted. (F) Graphic representation of colony counts with treatments as noted.
Data shown are representative of three independent experiments. Values that are
significantly different from empty vector control (TrxR2 overexpression) or DMSO
(Erucin treatment) are marked with an asterisk (*), and those significantly different from
tamoxifen treatment are marked with two asterisks (**). Data are presented as number of
colonies +/- SD. Values that are significantly different (p<0.05) from empty vector
control are marked with an asterisk (*).
Figure 2-LCC2
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Upregulation of cellular and mitochondrial thioredoxin reductase decreased DNA
synthesis in tamoxifen-treated tamoxifen-resistant LCC2 cells. Cells were treated to
overexpress thioredoxin reductase, then treated with either 0.1% DMSO or 1 μM
tamoxifen and 1 μM fulvestrant (positive control) for 48 hours. (A) Tamoxifen-resistant
LCC2 cells were transfected with pCMV6-XL4 plasmid to overexpress mitochondrial
thioredoxin reductase 2, then treated as noted in Materials and Methods section. (B)
LCC2 cells were treated with 10 μM Erucin for 48 hours in serum-free media.
Afterwards, starvation media was removed, fresh serum-free media added, and cells were
treated as noted. Data shown are representative of minimum three independent
experiments and are presented as absorbance reading +/- SD. Values that are significantly
different from empty vector control (TrxR2 overexpression) or DMSO (erucin treatment)
are marked with an asterisk (*), and those significantly different from tamoxifen
treatment are marked with two asterisks (**).

Downregulation of Jab1 also decreases DNA synthesis in tamoxifen-treated
tamoxifen-resistant LCC2 cells. (C) Cells were treated to underexpress Jab1, incubated
in serum-free media 48 hours, then treated with either 0.1% DMSO, 1 μM tamoxifen, or
1 μM fulvestrant (positive control) for 48 hours. Data shown are representative of
minimum three independent experiments and are presented as absorbance +/- SD. Values
that are significantly different from empty vector control are marked with an asterisk (*).
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Figure 3-LCC2

Upregulation of TrxR2 and TrxR2 with plasmid overexpression or isothiocyanate
treatment increases Trx2 and Trx expression in addition to TrxR2 and TrxR
expression in LCC2 cells. (A) LCC2 cells were transfected with plasmid to overexpress
TrxR2. Treatments were administered as noted in Materials and Methods section. (B)
LCC2 cells were serum starved 48 hours during which specified cells were treated with
10 μM sulforaphane. After starvation, media was replaced with fresh serum-free media,
and cells were treated as noted. Cells were collected after 48 hours for protein analysis.
Figure 4-LCC2
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Thioredoxin oxidation in tamoxifen resistant cells may be reversible. (A) Tamoxifenresistant LCC2 cells were transfected with pCMV6-XL4 plasmid to overexpress
mitochondrial thioredoxin reductase 2, and (B) LCC2 cells were treated with 10 μM
erucin for 48 hours in serum-free media. Cells were then exposed to either 0.1% DMSO
or 1 μM tamoxifen for 30 minutes. Cells were lysed and lysate run through redox western
protocol as noted in Materials and Methods section. Data shown are representative, and
are presented as (C) redox potential of thioredoxin.
Figure 5-LCC2
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Upregulation of cellular and mitochondrial thioredoxin reductase increases Jab1/
Trx binding and decrease Jab1 p27 binding in tamoxifen-treated tamoxifenresistant LCC2 cells. Cells were treated to overexpress thioredoxin reductase, then
treated with either 0.1% DMSO or 1 μM tamoxifen for 48 hours. LCC2 cells
overexpressing mitochondrial thioredoxin reductase by pretreatment with 10 μM
isothiocyanate for 48 hours in serum-free media were harvested for coimmunoprecipitation after 48 hours of treatment. (A) After immunoprecipitation of Jab1
with anti-Jab1 antibody, precipitated proteins were probed with anti-Trx antibody. Trx
binding was seen as greatly enhanced in sulforaphane pretreated/tamoxifen treated cells.
(B) After immunoprecipitation of Jab1, precipitated proteins were probed with anti-p27
antibody. Jab1/p27 binding was decreased as compared to cells without erucin pretreat.
Figure 6-LCC2
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Overexpression of TrxR1 through erucin treatment decreases p27 phosphorylation
at T157 and T187. LCC2 cells were serum starved 48 hours during which specified cells
were treated with 10 μM erucin. After starvation, media was replaced with fresh serumfree media, and cells were treated as noted. Cells were collected after 48 hours of
treatment for protein analysis. LCC2 cells were treated with 0.1% DMSO or 1 μM
tamoxifen. (A) Expression of phosphorylated p27 at T157 and T187 before and after
overexpression of TrxR2 and TrxR1 through erucin treatment. (B) Quantification of
protein expression (T157). Phosphorylated/total p27 ratio was normalized to β-actin. (C)
Quantification of protein expression (T187). Phosphorylated/total p27 ratio was
normalized to β-actin. Data shown are representative of two independent experiments and
are presented as protein expression amounts.

Underexpression of Jab1 decreases p27 phosphorylation at T187. LCC2 cells were
serum starved 48 hours, then media replaced with fresh serum-free media, and cells
treated with 0.1% DMSO or 1 μM tamoxifen. Cells were collected after 48 hours of
treatment for protein analysis. (A) Expression of phosphorylated p27 at T157 and T187
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with and without underexpression of Jab1. (B) Quantification of protein expression
(T157). Phosphorylated/total p27 ratio was normalized to β-actin. (C) Quantification of
protein expression (T187). Data shown are representative of two independent
experiments and are presented as protein expression amounts.

IV

INCREASED THIOREDOXIN REDUCTASE OR DECREASED JAB1
LEADS TO DECREASED GROWTH IN BREAST CANCER CELLS

UPON ESTROGEN TREATMENT THROUGH DECREASED AKT AND
P27 PHOSPHORYLATION

Abstract
It is known that estrogen increases ROS in breast cancer cells. Thioredoxin, an enzymatic
antioxidant, reduces proteins that have been oxidized by ROS. We wanted to show that
mild oxidants such as estrogen could oxidize thioredoxin, causing it to be inactive and
unable to reduce other proteins. This alteration in an antioxidant could lead to furthering
cell proliferation by changing the redox state of the cell and leading to an increase in cell
cycle pathways that lead to proliferation, such as the PI3K pathway. This increase in
proliferation signaling could be a pathway for resistance to treatments such as tamoxifen,
which has also been shown to produce ROS in low to medium doses. For this study we
looked at how overexpressing thioredoxin reductase or underexpressing Jab1 affects
estrogen-mediated cell proliferation in the breast cancer epithelial cell line MCF-7, as
well as the effects of oxidized thioredoxin on Akt and p27 phosphorylation. We show
that estrogen oxidizes thioredoxin, and that this is reversed with the overexpression of
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thioredoxin reductase. We also show that thioredoxin reductase overexpression in MCF-7
cells decreases Akt phosphorylation, increases p27 expression, and decreases p27
phosphorylation. This data implies a role for antioxidants in altering estrogen-mediated
growth of breast cancer cells. As we have already shown that it plays a role in altering
tamoxifen resistance in breast cancer cells, this data may imply a role for thioredoxin
reductase in preventing tamoxifen resistance.

Introduction
Estrogen actions with estrogen receptors are well known to promote pre-neoplastic and
malignant growth. The estrogen / estrogen receptor combination can directly interact with
the estrogen response element, or can act through a non-genomic pathway.1 Estrogen
mechanisms in breast cancer cells have more recently included the production of
intracellular ROS, leading to cell signaling and growth of estrogen-dependent breast
cancer cells.2 3 At moderate levels, ROS can use reversible protein oxidation to regulate
signaling pathways, most especially in PTPs.4 An important role of PTPs and PTKs is
their ability to turn on and off the action of the protein on which they are exerting their
influence.5 Structural changes to PTPs are induced by ROS, and the altered protein
conformation leads to signaling cascade upregulation.6 Oxidation of PTPs can be
reversed by thiol compounds7 such as thioredoxin (Trx), a 12 kDa disulphide reducing
enzyme8, 9 that is induced by stressors such as 17β-estradiol.10
The redox state of Trx is important to its function, and as such, the role of Trx reductase
(TrxR) is key. In both Trx and TrxR there are cysteine molecules that are key to redox
regulation.8, 9 Trx reductases are NADPH-dependent, and they catalyze disulfide
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reduction at thioredoxin active sites. In turn, reduced thioredoxins catalyze the movement
of active site dithiols to a disulfide state. This process has given the thioredoxin family a
crucial role in cell-growth and apoptosis, as it is through this process they can regulate
enzymes such as ribonucleotide reductase, peroxiredoxins and transcription factors.11

The PTP PTEN is a phosphoinositol 3’ kinase (PI3K) inhibitor. A downstream molecule
in the PI3K pathway, protein kinase B (Akt), can phosphorylate p27 at T157 and inhibit
its import to the nucleus, prohibiting p27 from inhibiting cell proliferation.12
Overexpression of the PTEN gene increases p27 levels, decreases cyclin D1 levels,
inhibits the phosphorylation of Akt, and through these mechanisms inhibits cell growth in
MCF-7 cells.13 The tumor suppressor PTEN can be reduced by Trx.14

Several studies have explored the link between estrogen, estrogen receptor (ER) and
thioredoxin. For example, the breast cancer cell line ZR-75-1 has been used to show that
H2O2 treatment leads to a decrease in levels of pS2, a gene induced by estrogen. When,
however, cells were transfected with thioredoxin, the expression of pS2 was restored in
the H2O2-treated cells.15 Another study has shown that Trx expression may be correlated
with better prognosis in ER+ and p53-intact patients.16 In the mouse uterus, estrogen
treatment increases Trx, Trx2, and TrxR expression, as evidenced by mRNA levels.17 In a
study regarding estrogen and congestive heart failure, subcutaneous, slow release pellets
of estrogen (0.5 mg/60 day release) offered antioxidative properties. These properties
were also associated with an increase in the expression of Trx, TrxR, and TrxR activity.
In this form, estrogen also reduced ASK-1 activation, JNK activation, and p38 MAPK,
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which can all be related to the increase in availability of thioredoxin. These data may
show that thioredoxin could be conferring the antioxidative properties that are being
linked to estrogen.18

In considering breast cancer and its treatment, it is important to also explore the cell
signaling pathways that occur due to estrogen exposure in ER+ cells, as well as those
initiated by the treatments. While both Trx mRNA and protein are increased with 17βestradiol treatment, this effect is suppressed when tamoxifen treatment is given.10 Both
estrogen and tamoxifen have been shown to increase levels of ROS in breast cancer
cells.19 ROS can initiate signal transduction cascades that have been shown to lead to cell
proliferation.3 In this study, we explore the role thioredoxin may have in reversing
estrogen-mediated cell signaling. In particular, we look at the effect of oxidized Trx on
PTEN function, as well as the downstream targets of Akt and phosphorylated p27. We
find that altering the oxidative state of breast cancer cells with thioredoxin reductase
leads to a decrease in cell growth through decreasing Akt phosphorylation, and
subsequently decreasing phosphorylation of p27 at T157.

Materials and methods
Cell lines and cultures: Human breast adenocarcinoma MCF-7 cells were propagated in
phenol red free Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) with L-Glutamine
and 15mM HEPES (Invitrogen, Grand Island, NY; Mediatech, Manassas, VA) containing
10% (v/v) fetal bovine serum (Invitrogen; Atlanta Biologicals Lawrenceville, GA),
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100 u/mL penicillin G sodium, and 100 ug/mL streptomycin sulfate (Invitrogen) at 37 °C
in 5% CO2 atmosphere.

Antibodies: All antibodies used were purchased from Santa Cruz (Santa Cruz, CA),
except the following: GAPDH (Sigma), β-actin (Sigma), and p27 phosphorylated at T157
(Abcam, Cambridge, MA).

Chemicals and experimental protocol: Erucin was purchased from LKT Laboratories (St.
Paul, MN). DMSO and 17β-estradiol were purchased from Sigma (St. Louis, MO). For
experimental purposes, cells were seeded in 10% FBS DMEM/F12 medium and allowed
to adhere overnight. Culture medium was replaced with serum-free DMEM/F12 and
allowed to grow for 48 h (starvation), followed by treatments as described in figure
legends. For cells with erucin treatment, 10 μM erucin was added with the DMEM/F12
without FBS for the starvation period of 48 h in order to overexpress thioredoxin
reductase 1 (TrxR1). Media with erucin was then removed, fresh serum-free media added
without erucin, and treatments added.

Transfection procedures: pRS shRNA vector without shRNA cassette insert, pRS HuSH
29mer shRNA constructs against COPS5 (Jab1), and pCMV6-XL4 carrying the fulllength human TrxR2 cDNA (OriGene Technologies, Rockville, MD, USA) were purified
using MAX Efficiency® DH5α™ Competent Cells (Invitrogen) and plasmid was
extracted using phenol extraction and ethanol precipitation. For transfection, cells were
seeded in 6-well plates at 70%. After overnight incubation, transfection was performed
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using Fugene (1:3) (Roche, Indianapolis, IN) and left to incubate overnight in Optimem
(Invitrogen) or DMEM/F12 without serum or antibiotics. The next day media was
changed to growth media, and cells were seeded the following day. HuSH 29-mer non-effective (scrambled) pRS vector (Origene) was tested and showed similar actions to the
empty plasmid vector (data not shown).

Soft agar colony formation assay: Cells were seeded at a concentration of 500 cells/well
(48-well plates) in 0.25% agarose on a 0.5% agarose base in DMEM/F12 with 10% FBS.
Cells were fed two times per week with treatments as described in figure legends, and
colonies were counted on day 16. Each assay was performed with triplicate treatments.

BrdU cell proliferation assay: Cells were seeded at 2500 cells/well in 96-well plates in
serum-free DMEM/F12 for 48 h (certain wells also including 10 μM erucin as described
earlier). Treatments were added as described in figure legends for 48 h. A colorimetric
BrdU cell proliferation assay was performed according to the manufacturer’s instructions
(Roche). After incubation, the cells were labeled with BrdU for 24 hours at 37° C in 5%
CO2. After 30 m of fixation/denaturing, cells were incubated with anti-BrdU-peroxidase
antibody (1:1000) for 90 m. Cells were then washed three times with 1x PBS, and the
final substrate added. The absorbance was measured at a wavelength of 370 nm and a
reference wavelength of 492 nm at time points from 5-30 m at 5 m intervals.
Immunoblot: Cells were seeded in 100mm plates at 1 x106 cells in 10% FBS DMEM/F12
and allowed to grow overnight. Cells were then starved for 48 hours, then treated with
DMSO and 17β-estradiol (E2) for 48 h. Cells were then rinsed with cold PBS, lysed (150
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mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (sodium dodecyl sulphate),
50 mM Tris, pH 8.0 0.2mM Na3VO4, 50mM NaF, 1x complete protease inhibitor
(Roche)), and proteins isolated. Quantification of proteins was performed using the BCA
assay (Pierce, Rockford, IL), and lysate was boiled for 5 m at 95-100° C. Acrylamide gel
(12%) was loaded with 100 μg protein, and run for 2.5 h at 150 volts. Proteins were
transferred to PVDF, and blots were blocked with either 5% milk or blocking buffer for
phosphorylated proteins (1% milk, 1% BSA, 50 mM NaF) in TBS-T. Blots were then
incubated with primary antibodies overnight. Secondary antibodies were added for one
hour, and blots were developed using either a film developer (Konica Minolta) or
VersaDoc imaging system using QuantityOne software (BioRad). ImageJ software (NIH)
was used to quantify the protein expression through densitometry. This software was
used for all assays that required densitometry.

PTEN Redox Western: Cells were seeded in 6 well plates at 400,000 cells / well in 10%
FBS DMEM/F12 and allowed to grow overnight. Cells were then grown in DMEM/F12
without serum for 48 h, and then treated with DMSO and 17β-estradiol for 30 m in 1 mL
of starvation media. Cells were scraped in the media and treatment, and placed in 1.5 mL
tube containing 200 uL of ice-cold 50% trichloroacetic acid. Cells and media were
sonicated briefly, and then centrifuged at 2000 x g for 5 m. Supernatant was removed,
and the pellet was washed with acetone. After centrifuging again, supernatant was
removed, and 200 uL lysis buffer was added (100 mm Tris-HCl (pH 6.8), 2% SDS, 40
mM NEM). 30-50 uL of lysate was run under non-reducing conditions using SDS-PAGE.
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Thioredoxin Redox Western: The procedure for redox western for thioredoxin has been
described in detail.20 Briefly, MCF-7 cells were seeded at either 400,000 cells / well (6
well plate) or 1 x 106 cells/plate (100 mm plates). After overnight incubation, serum-free
media was added to all wells, with 10 μM erucin added to certain wells/plates. After 48 h,
cells were treated as noted in figures for 30 m. After washing 2x with PBS, G lysis buffer
with 50 mM iodoacetic acid was added and cells were scraped into 1.5 mL tubes.
Samples were incubated for 30 m at 37°. Lysate was sonicated briefly, then centrifuged
for 3 m at 2000 x g at room temperature. Lysate was transferred to new tubes, and BCA
assay was performed to quantitate the proteins. 50 μg was loaded in a native separating
gel (15%) under non-reducing conditions and run for 90 m at 150V in native running
buffer. Proteins were transferred to PVDF, incubated in 5% BSA for 1 h, then incubated
in anti-Trx antibody overnight. An SDS-PAGE (12%) was also run with the same lysate
for loading control GAPDH or B-actin. Films or Versadoc images were subjected to
densitometry using ImageJ software.

Redox potential (Eh) of Trx1 was calculated using the Nernst equation through the use of
the reduced and oxidized bands of thioredoxin. The equation
Eh (mV, redox potential) = Eo (midpoint potential) + (RT/nF) ln(Trx1Ox /Trx1Red) was
used, where Eo = -240 mV for Trx1 at pH 7.0 and 25°C, 30=ln and RT/nF (this was
calculated previously by Go and Jones by using values [R, universal gas constant; T,
absolute temperature; n, number of electrons; F, Faraday constant]). The ratio of oxidized
and reduced Trx1 bands (Trx1 Ox/Trx1 Red) band intensities were taken for each sample
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and used to calculate ln(Trx1Ox /Trx1Red). Thus, the final equation (as calculated by Go
and Jones) reduces to Eh, Trx1 = −240 mV + 30 × ln(ratio of Trx1Ox and Trx1Red).

Results
Upregulation of TrxR or downregulation of Jab1 suppresses anchorageindependent growth and DNA synthesis in estrogen-treated MCF-7 cells
Estrogen is known to lead to cell growth in MCF-7 cells. Our lab has shown the induction
of mitochondrial ROS (mtROS) in estrogen-dependent breast cancer cells upon estrogen
treatment. We have also shown the effect of antioxidants, such as ebselen and NAC, on
reducing these mtROS, and subsequently on the reduction of estrogen-mediated growth
in MCF-7 cells. For these experiments, we wanted to explore the role of thioredoxin
reductase 1 and 2 on estrogen-mediated growth in MCF-7 cells.

Anchorage-independent growth is a hallmark of tumor cells. As such, we performed a
colony formation assay in soft agar with MCF-7 cells, MCF-7 cells transfected with Jab1
shRNA to underexpress Jab1, MCF-7 cells transfected to overexpress TrxR2, and MCF-7
cells that were co-treated with erucin to increase TrxR1. Cells were treated for over 2
weeks, and colonies counted. Figures 1A, 1B, and 1C show representative pictures and
graphic representations of these counts. We found that the overexpression of TrxR2
through transfection and TrxR1 through the treatment with erucin decreased both DMSO
and estrogen treated cells significantly. (Figure 1A and 1B) Underexpression of Jab1 also
showed a decrease in estrogen-treated cells. (Figures 1C and 1F) These data show a role
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for increased reduced thioredoxin or decreased Jab1 expression in reducing estrogenmediated growth of tumor cells.

We also looked at the DNA synthesis (cell proliferation) of these cells through the use of
the BrdU incorporation assay (Figures 2A, 2B, and 2C) and found that all three cellular
modulations led to a decrease in DNA synthesis. These data suggest that an increase of
thioredoxin reductase, both cellular and mitochondrial, will decrease estrogen-mediated
growth of MCF-7 epithelial cancer cells, supposedly through the reduction of thioredoxin
1 and thioredoxin 2 and subsequent reduction of other cell cycle proteins. It also suggests
a role for Jab1 in estrogen–mediated growth of breast cancer.

Thioredoxin is reversibly oxidized by estrogen treatment, and reduced after the
upregulation of TrxR
Estrogens are phenolic chemicals, (Roy and Liehr, 1990) and are known to lead to the
production of mitochondrial ROS.19, 21 MtROS have been implicated in cell signaling in
several pathways, including integrins, platelet-derived growth factor, epidermal growth
factor, and nerve growth factor.22 We confirmed the increase of ROS by estrogen by
measuring H2O2 production through the DCF assay. (Data not shown) One of the three
major redox couples that are responsive to changes in the reducing/oxidizing (redox)
environment in cells is Trx(SS)/Trx(SH)2.23 There are several published examples of
Trx’s susceptibility to ROS, and there are a variety of compounds that have been found to
oxidize Trx, such as H2O2 and superoxide.24 While it has been shown that estrogen
treatment increases thioredoxin and thioredoxin reductase levels in bovine aortic
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endothelial cells, we wanted to test if the mtROS produced by estrogen would have an
oxidative effect on thioredoxin. We performed a redox western to explore the effects of
estrogen treatment on the redox state of thioredoxin. Cells were treated for 30 m before
lysates were prepared. 50 mM iodoacetic acid was used in 6M guanidine lysis buffer, as
it leads to thiol alkylation. When a thiol is modified, one negative charge is added, and
reduced thioredoxin, which will have a negative charge after IAA treatment, will run
faster than oxidized thioredoxin in a native, non-reducing gel electrophoresis.20

We found that estrogen treatment increases thioredoxin oxidation (Figure 3A) and,
utilizing the Nernst equation as described in Materials and Methods, found that estrogen
decreases thioredoxin redox potential (Figure 3B). The dietary isothiocyanates
sulforaphane, erucin, and iberin have been found to induce thioredoxin reductase in
MCF-7 cells.25 We wanted to explore if this chemical induction of TrxR would change
the redox state of thioredoxin that was oxidized by estrogen. In HepG2 and
undifferentiated Caco-2 cells, not only does sulforaphane induce TrxR, but also its
substrate Trx.26 We found this to also be true of pretreating with erucin on the MCF-7 sub
line LCC-2 cells.

We found that there is an overall increase in thioredoxin due to erucin treatment, and
there is an increase in the amount of reduced thioredoxin in erucin+estrogen-treated cells
in relation to those treated with the vehicle (DMSO). Erucin, however, also increases the
amount of both TrxR and Trx, and has been shown to increase oxidation of glutathione
reductase, thioredoxin reductase and peroxiredoxin 3. We found that the redox potential
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of thioredoxin went down with isothiocyanate treatment, but feel this avenue deserves
further research, as the amount of reduced thioredoxin increased dramatically. As the
goal of this experiment was to ensure an increase in reduced thioredoxin, and not
necessarily only an increase in oxidized/reduced thioredoxin ratio, we felt the use of
isothiocyanates achieved this goal.

We explored if increasing the mitochondrial thioredoxin reductase (TrxR2) through
transfection would have an effect on the oxidative state of cellular thioredoxin. (Figures
3C and 3D) We found that not only is there a decrease in the oxidation level of Trx (and
an increase in redox potential) after this overexpression, there is an unexpected increase
in thioredoxin redox potential when Jab1 is underexpressed.

These experiments show that the oxidation of thioredoxin by estrogen can be reduced
with the use of an overexpression of thioredoxin reductase or the underexpression of
Jab1. The oxidation of Trx can lead to its inactivity, which can affect several cell
signaling pathways. For this study we explored PTEN oxidation and thioredoxin’s role in
reducing PTEN and restoring its function.

Upregulation of TrxR through transfection decreases the ratio of oxidized to
reduced PTEN
ROS plays a redox regulatory role in protein-tyrosine phosphatases (PTPs). Its signature
motif allows for redox regulation of proteins when the cysteine residues react with ROS.4
The PTP catalytic cysteine only requires mild oxidative conditions to be oxidized to
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sulfenic acid (Cys-SOH). This can be averted by interactions with a protein structure such
as a thiol.4, 5, 27, 28 We first checked for oxidation of PTEN by estrogen through nonreducing SDS-PAGE. MCF-7 cells were transfected with TrxR2 or pretreated with
erucin, then treated with estrogen for 30 m. We found that cells that were transfected with
thioredoxin reductase reduced the ratio of oxidized/reduced PTEN in cells treated with
estrogen (Figure 4A and B) We did not see similar results in cells pretreated with erucin
to overexpress TrxR (data not shown). This may be due to the treatment time used.

Downstream signaling of phosphorylated Akt is altered by modulation of
thioredoxin reductase and Jab1
PTEN is known to inhibit phosphoinositol 3’ kinase (PI3K). A downstream molecule in
the PI3K pathway is protein kinase B (Akt), which can phosphorylate, and thus
inactivate, the cell cycle inhibitor p27. We wanted to explore if the oxidation or oxidation
and then reduction of PTEN had an effect on this pathway. We performed a western blot
on MCF-7 cells that had been treated with estrogen, pretreated with erucin and/or
transfected with TrxR2 cDNA or Jab1 shRNA. We found that while estrogen increases
the expression of phosphorylated Akt at S473, increasing the expression of thioredoxin
reductase 2 alters this estrogen-mediated phosphorylation, as seen in Figure 5A and B.
We were not able to show that the chemical overexpression of TrxR through the use of
erucin also decreases phosphorylation of Akt (data not shown). Again, this could be due
to the treatment times chosen for this experiment. However, again unexpectedly, the
downregulation of Jab1 also showed a decrease in Akt phosphorylation.
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Overexpression of TrxR or underexpression of Jab1 alters p27 phosphorylation
at T157
Protein kinase B (Akt) can phosphorylate p27 at T157 and inhibit its import to the
nucleus. This prohibits p27 from inhibiting cell proliferation.12 When p27 is in the
cytoplasm, it aids in the assembly of cyclin D1/cdk4, which furthers cell proliferation.29
When the PI3K pathway has been activated, as it is in human cancers, it has been found
that p27 concentrations decrease. This effect is reversed by PTEN.30 Overexpression of
the PTEN gene increases p27 levels, decreases cyclin D1 levels, inhibits the
phosphorylation of Akt, and through these mechanisms inhibits cell growth in MCF-7
cells.13 We wanted to explore the effect of an increase of thioredoxin through an
overexpression of thioredoxin reductase on p27 phosphorylation at T157. We performed
a western blot as outlined in the Materials and Methods section (Figure 6A and D). We
underexpressed Jab1 and overexpressed TrxR2 and pretreated with erucin to overexpress
both cellular and mitochondrial TrxR (TrxR1 and TrxR2 respectively) and treated as
noted in figures. We also scanned the blots and used ImageJ to quantify the blots (Figures
6B, 6C, 6E, 6F). We found that the overexpression of both TrxR1 and TrxR2 led to a
decrease in the PTEN downstream target of p27 phosphorylation at T157. This data
paired with the data on PTEN shows a possible link between the oxidation of thioredoxin,
oxidation of PTEN, and cell cycle progression through T157 phosphorylation of p27.

Discussion
Estrogen and tamoxifen produce intracellular ROS rapidly, which can lead to cell
signaling and the growth of estrogen-dependent breast cancer cells.2, 3, 19 Upon ROS
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production there is a stimulus and a response to the ROS from a protein of either
activation or inhibition, which is amplified through the activation or inhibition of effector
molecules further downstream in the pathway. There is also reversibility so that the
pathway can be responsive to more than just the one stimulus. Thioredoxin and
glutathione, as well as enzymes that are associated with each, have been found to reduce
the thiol oxidation that occurs through ROS. It has been compared to the regulatory effect
of phosphorylation and de-phosphorylation of proteins.31

Thioredoxin and glutathione are the major factors in maintaining reduced proteins,6, 32, 33
and these reducing agents are found, in normal cells, in their reduced form. When they
perform their reduction actions on oxidized proteins, they themselves are oxidized.
They are then returned to their reduced forms through the use of thioredoxin reductase
and glutathione reductase, respectively. Cysteine residues have been found to be specific
targets for ROS when in the thiolate (-S) form, making them susceptible to modification
by ROS.

Trx has been found to compete with p27 for binding with Jab1 in HEK293T (human
embryonic kidney) cells, and, through this, negatively regulate p27 degradation. It has
been shown that the addition of Trx to cells altered the direction of Jab1-induced p27
level decrease. In our study, we both overexpressed thioredoxin reductase to increase the
amount of reduced, and thus active, thioredoxin, and underexpressed Jab1 through
shRNA transfection to show a possible role for this pathway. We used these treatments
on MCF-7 breast cancer cells to explore if altering the redox state of cells will alter
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estrogen-mediated growth. We found that overexpression of both thioredoxin reductase 1
and 2 reduces colony formation and cell proliferation effects of estrogen. We saw the
same effects when we reduced Jab1 expression.

We explored the oxidation of thioredoxin by estrogen, and found that in MCF-7 cells
thioredoxin is oxidized by estrogen. Overexpressing thioredoxin reductase, as would be
expected, reversed these effects of estrogen. Interestingly, the reduction of Jab1
expression also led to a reduction in thioredoxin oxidation. We are unsure of the
signaling pathway that may lead to this increase in redox potential by Jab1, and feel it
deserves further study.

Particularly susceptible to oxidation are protein tyrosine phosphatases (PTPs).27, 28 PTEN
can be oxidized by H2O2, and then reduced by Trx.14 We found that estrogen-induced
ROS oxidizes PTEN in MCF-7 cells, and that the addition of thioredoxin reductase
reduces this oxidation. PTEN, as well as other PTPs, has been show to correlate with p27
levels. We wanted to explore if this pathway was affected by TrxR overexpression or
Jab1 underexpression. A downstream molecule in the phosphoinositol 3’ kinase (PI3K)
pathway, protein kinase B (Akt) can phosphorylate p27 at T157 and inhibit its import to
the nucleus. This prohibits p27 from inhibiting cell proliferation12 and makes it available
for cyclin D1/cdk4 assembly which furthers cell cycle progression.29 When the PI3K
pathway has been activated, as it is in human cancers, it has been found that p27
concentrations decrease.30 We looked at the phosphorylation of Akt, and found it to be
susceptible to estrogen and enzymatic antioxidants. The overexpression of thioredoxin
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reductase, presumably through the reduction of oxidized thioredoxin and subsequent
reduction of oxidized PTEN, led to a decrease in phosphorylated Akt at S473. This
decrease was also seen in cells that underexpressed Jab1. Further downstream in this
pathway, the phosphorylation of p27 at T157 was decreased by altering TrxR and Jab1
levels in the cells.

Reference List
(1) Coleman KM, Smith CL. Intracellular signaling pathways: nongenomic actions of
estrogens and ligand-independent activation of estrogen receptors. Front Biosci
2001;6:D1379-D1391.
(2) Roy D, Felty Q, Narayan S, Jayakar P. Signature of mitochondria of steroidal
hormones-dependent normal and cancer cells: potential molecular targets for
cancer therapy. Front Biosci 2007;12:154-173.
(3) Felty Q, Roy D. Estrogen, mitochondria, and growth of cancer and non-cancer
cells. J Carcinog 2005;4(1):1.
(4) Salmeen A, Barford D. Functions and mechanisms of redox regulation of
cysteine-based phosphatases. Antioxid Redox Signal 2005;7(5-6):560-577.
(5) Kang SW. Two axes in platelet-derived growth factor signaling: tyrosine
phosphorylation and reactive oxygen species. Cell Mol Life Sci 2007;64(5):533541.
(6) Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals
and antioxidants in normal physiological functions and human disease. Int J
Biochem Cell Biol 2007;39(1):44-84.
(7) Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during
receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003;28(9):509514.
(8) Nguyen P, Awwad RT, Smart DD, Spitz DR, Gius D. Thioredoxin reductase as a
novel molecular target for cancer therapy. Cancer Lett 2006;236(2):164-174.
(9) Kondo N, Nakamura H, Masutani H, Yodoi J. Redox regulation of human
thioredoxin network. Antioxid Redox Signal 2006;8(9-10):1881-1890.

123

(10) Maruyama T, Sachi Y, Furuke K et al. Induction of thioredoxin, a redox-active
protein, by ovarian steroid hormones during growth and differentiation of
endometrial stromal cells in vitro. Endocrinology 1999;140(1):365-372.
(11) Chang EY, Son SK, Ko HS, Baek SH, Kim JH, Kim JR. Induction of apoptosis
by the overexpression of an alternative splicing variant of mitochondrial
thioredoxin reductase. Free Radic Biol Med 2005;39(12):1666-1675.
(12) Liang J, Zubovitz J, Petrocelli T et al. PKB/Akt phosphorylates p27, impairs
nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med
2002;8(10):1153-1160.
(13) Weng LP, Brown JL, Eng C. PTEN coordinates G(1) arrest by down-regulating
cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid
phosphatase activity in a breast cancer model. Hum Mol Genet 2001;10(6):599604.
(14) Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of
the tumor suppressor PTEN by H2O2. J Biol Chem 2002;277(23):20336-20342.
(15) Hayashi S, Hajiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J, Tanaka H.
Functional modulation of estrogen receptor by redox state with reference to
thioredoxin as a mediator. Nucleic Acids Res 1997;25(20):4035-4040.
(16) Matsutani Y, Yamauchi A, Takahashi R et al. Inverse correlation of thioredoxin
expression with estrogen receptor- and p53-dependent tumor growth in breast
cancer tissues. Clin Cancer Res 2001;7(11):3430-3436.
(17) Deroo BJ, Hewitt SC, Peddada SD, Korach KS. Estradiol regulates the
thioredoxin antioxidant system in the mouse uterus. Endocrinology
2004;145(12):5485-5492.
(18) Satoh M, Matter CM, Ogita H et al. Inhibition of apoptosis-regulated signaling
kinase-1 and prevention of congestive heart failure by estrogen. Circulation
2007;115(25):3197-3204.
(19) Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P. Role of
mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.
Apoptosis 2005;10(6):1395-1410.
(20) Go YM, Jones DP. Thioredoxin Redox Western Analysis . Current Protocols in
Toxicology Supplement 41 2009.
(21) Roy D, Cai Q, Felty Q, Narayan S. Estrogen-induced generation of reactive
oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J
Toxicol Environ Health B Crit Rev 2007;10(4):235-257.

124

(22) Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J
Physiol Lung Cell Mol Physiol 2000;279(6):L1005-L1028.
(23) Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the
redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med
2001;30(11):1191-1212.
(24) Lemarechal H, Anract P, Beaudeux JL, Bonnefont-Rousselot D, Ekindjian OG,
Borderie D. Impairment of thioredoxin reductase activity by oxidative stress in
human rheumatoid synoviocytes. Free Radic Res 2007;41(6):688-698.
(25) Wang W, Wang S, Howie AF, Beckett GJ, Mithen R, Bao Y. Sulforaphane,
erucin, and iberin up-regulate thioredoxin reductase 1 expression in human MCF7 cells. J Agric Food Chem 2005;53(5):1417-1421.
(26) Bacon JR, Plumb GW, Howie AF, Beckett GJ, Wang W, Bao Y. Dual action of
sulforaphane in the regulation of thioredoxin reductase and thioredoxin in human
HepG2 and Caco-2 cells. J Agric Food Chem 2007;55(4):1170-1176.
(27) Salmeen A, Barford D. Functions and mechanisms of redox regulation of
cysteine-based phosphatases. Antioxid Redox Signal 2005;7(5-6):560-577.
(28) Chiarugi P, Buricchi F. Protein tyrosine phosphorylation and reversible oxidation:
two cross-talking posttranslation modifications. Antioxid Redox Signal
2007;9(1):1-24.
(29) Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM.
mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol
Cell 2008;30(6):701-711.
(30) Alkarain A, Slingerland J. Deregulation of p27 by oncogenic signaling and its
prognostic significance in breast cancer. Breast Cancer Res 2004;6(1):13-21.
(31) Cooper CE, Patel RP, Brookes PS, rley-Usmar VM. Nanotransducers in cellular
redox signaling: modification of thiols by reactive oxygen and nitrogen species.
Trends Biochem Sci 2002;27(10):489-492.
(32) Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals
and antioxidants in normal physiological functions and human disease. Int J
Biochem Cell Biol 2007;39(1):44-84.
(33) Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin
reductase. Eur J Biochem 2000;267(20):6102-6109.

125

Figures
Figure 1-MCF7
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Upregulation of cellular and mitochondrial thioredoxin reductase reduces the
formation of anchorage–independent colonies in estrogen-treated ER+ breast
cancer epithelial cells. MCF-7 cells were transfected to overexpress TrxR2 or were
treated chemically with 10 μM erucin to overexpress TrxR1 and seeded in 0.25% agarose
with DMEM and 10% FBS. Cells were treated with either 0.1% DMSO or 100 pg E2 for
over two weeks. (A & B) Representative pictures of wells demonstrating colonies formed
by MCF-7 cells transfected and/or treated as indicated. Also shown, graphic
representation of colony counts. Data shown are representative of three independent
experiments and are presented as number of colonies +/- SD. Values that are significantly
different (p<0.05) from empty vector control (TrxR2 overexpression) or DMSO (erucin
treatment) are marked with an asterisk (*).

Downregulation of Jab1 reduced the formation of anchorage–independent colonies
in estrogen-treated ER+ breast cancer epithelial cells. MCF-7 cells were transfected
with the HuSH pRS plasmid to underexpress Jab1. Wild type cells and cells
underexpressing Jab1 were treated with either 0.1% DMSO or 100 pg E2 in soft agar for
over 14 days. (C) Representative pictures of wells demonstrating colonies formed by
MCF-7 cells transfected and treated as indicated. Also shown, graphic representation of
colony counts. Data shown are a representative of two independent experiments
performed in triplicate and are presented as number of colonies +/- SD. Values that are
significantly different (p<0.05) from empty vector control are marked with an asterisk (*)
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Figure 2-MCF7

Upregulation of cellular and mitochondrial thioredoxin reductase decreased DNA
synthesis in estrogen-treated MCF-7 cells. Cells were treated to overexpress
thioredoxin reductase, and then treated with either 0.1% DMSO or 100 pg E2 for 48
hours. (A) MCF-7 cells were transfected with pCMV6-XL4 plasmid to overexpress
mitochondrial thioredoxin reductase 2, then treated as noted in the Materials and Methods
section. (B) MCF-7 cells were treated with 10 μM erucin for 48 hours in media without
FBS. Afterwards, starvation media was removed, fresh media added, and treatments as
noted were added. BrdU assay was performed as noted in Materials and Methods section.
Data shown are representative of minimum three independent experiments and are
presented as absorbance reading +/- SD. Values that are significantly different from
empty vector (TrxR2 overexpression) or DMSO (erucin treatment) are marked with an
asterisk (*).

128

Downregulation of Jab1 decreased DNA synthesis in estrogen-treated MCF-7 cells.
Cells were treated to overexpress thioredoxin reductase, and then treated with either 0.1%
DMSO or 100 pg E2 for 48 hours. Data shown are representative of minimum three
independent experiments and are presented as absorbance reading +/- SD. Values that are
significantly different from empty vector control (TrxR2 overexpression) or DMSO
(erucin treatment) are marked with an asterisk (*).
Figure 3-MCF7
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Estrogen increases oxidative state of MCF-7 cells and leads to an increase in
oxidation of Trx1. TrxR2 overexpression increases Trx redox potential. MCF-7 cells
were seeded to 10-6 in 100 mm plates. After incubating overnight, cells were incubated
with serum-free media for 48 hours. During this time, noted plates were treated with 10
μM erucin. After 48 hour incubation, cells were treated for 30 minutes with 0.1% DMSO
or 100 pg (100 ng in WT cells) 17β-estradiol. Cells were harvested in 50 mM guanidine
lysis buffer and prepared as described in Materials and Methods. (A) MCF-7 cells were
treated with 10 μM erucin for 48 hours in serum-free media, and (C) MCF-7 cells were
transfected with pCMV6-XL4 plasmid to overexpress mitochondrial thioredoxin
reductase 2. Cells were then exposed to either 0.1% DMSO or 100 pg E2 for 30 minutes.
Cells were lysed and lysate run through redox western protocol as noted in Materials and
Methods section. Data for DTT (reductant) and H2O2 (oxidant) are also shown. (B & D)
Data are presented as redox potential of thioredoxin. Data shown are representative of
three independent experiments and are presented as protein expression amounts and
redox potential values (Nernst equation).

Jab1 downregulation increases Trx redox potential. MCF-7 cells were seeded to 10-6
in 100 mm plates. After incubating overnight, cells were incubated with serum-free
media for 48 hours. After 48 hour incubation, cells were treated for 30 minutes with 0.1%
DMSO or 100 pg 17β-estradiol. Cells were harvested in 50 mM guanidine lysis buffer
and prepared as described in Materials and Methods. (C) MCF-7 cells were transfected to
downregulate Jab1. Cells were then exposed to either 0.1% DMSO or 100 pg E2 for 30
minutes. Cells were lysed and lysate run through redox western protocol as noted in
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Materials and Methods section. (D) Data are presented as redox potential of thioredoxin.
Data shown are representative of three independent experiments and are presented as
protein expression amounts and redox potential values (Nernst equation).
Figure 4-MCF7

Oxidation of PTEN by estradiol is reversed with overexpression of thioredoxin
reductase. MCF-7 cells overexpressing TrxR1 (erucin pretreat) and TrxR2
(transfection) were treated with 0.1% DMSO for 20 minutes or 100 pg 17β-estradiol
for 20 or 30 minutes after 48-hour incubation in serum-free medium. Cells were
harvested as noted in Materials and Methods section. (A) Oxidation of PTEN is shown
in EV (control) transfected cells, though not seen in TrxR2 transfected cells. (B)
Quantification of oxidized PTEN/reduced PTEN ratio. Data are representative of two
independent experiments.
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Figure 5-MCF7

Overexpression of thioredoxin reductase and underexpression of Jab1 decreases
Akt phosphorylation at Ser473 in estrogen-treated MCF-7 cells. Transfected or
chemically treated MCF-7 cells were treated with 0.1% DMSO or 100 pg 17β-estradiol.
(A) Expression of phosphorylated Akt before and after overexpression of TrxR2 or
underexpression of Jab1. (B) Quantification of protein expression. E2 time point shown is
30-minute treatment. Akt was normalized to β-actin first. The graph shown is
phosphorylated Akt/total normalized Akt ratio. Data shown are representative of two
independent experiments and are presented as protein expression amounts as quantified
by densitometry.
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Figure 6-MCF7
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Overexpression of TrxR1 through erucin treatment decreases p27 phosphorylation
at T157. MCF-7 cells were treated with 0.1% DMSO or 100 pg 17β-estradiol. (A)
Expression of p27 and phosphorylated p27 at T157 with and without overexpression of
TrxR2. (B) Quantification of relative p27 protein expression. (C) Quantification of
relative phosphorylated p27 expression. Phosphorylated/total p27 ratio was normalized to
β-actin. (D) Expression of p27 and p27 phosphorylated at T157 after overexpression of
TrxR. (E) Quantification of relative p27 protein expression. (F) Quantification of ratio of
phosphorylated/total p27, normalized to β-actin. Data shown are representative of two
independent experiments and are presented as protein expression amounts and redox
potential values.

Underexpression of Jab1 decreases p27 phosphorylation at T157. MCF-7 cells were
transfected to underexpress Jab2, incubated in serum-free media 48 hours, then treated
with 0.1% DMSO or 100 pg 17β-estradiol. (A) Expression of phosphorylated p27 at
T157 (B) Quantification of protein expression. Phosphorylated/total p27 ratio was
normalized to β-actin. Data shown are representative of two independent experiments and
are presented as protein expression amounts and redox potential values.

V CONCLUSION
The purpose of this research was to explore the enigmatic problem of tamoxifen
resistance in breast cancer through looking at the p27/Jab1/Trx pathway. The sub goals
were twofold: First, to show that reducing oxidized thioredoxin through increasing
thioredoxin reductase or that decreasing Jab1 protein can alter p27 phosphorylation;
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second, to show these same cellular alterations can increase tamoxifen sensitivity in
previously tamoxifen-resistance breast cancer cells.

Results of this study add several significant findings to research on tamoxifen resistance
and the p27/Jab1/Trx pathway. While there is one study that explores glutathione actions
on MKP3 phosphatase in antiestrogen resistance, there appear to be no other studies that
consider the role of reactive oxygen species in tamoxifen resistance. Further, the studies
that involve thioredoxin and chemotherapeutic resistance look at the chemotherapeutics
that use a high level of reactive oxygen species to kill breast cancer, and show that
thioredoxin interferes with cellular death in these cases. No other study looks at the level
of ROS produced by antiestrogens and how thioredoxin alteration by this ROS may affect
the possibility of resistance. Findings in this study showed that thioredoxin is oxidized by
physiologic levels of estrogen, and that reversal of this oxidation through the
overexpression of thioredoxin reductase can lead to previously tamoxifen-resistant cells
appearing to regain sensitivity.

There is one study out that shows that p27 and thioredoxin compete for binding to Jab1,
and when thioredoxin is not available for binding that Jab1 can bind to p27 and aid in
removing it from the nucleus. The current study explored the relationship between these
three proteins in tamoxifen-resistant breast cancer cells. While a thioredoxin/Jab1
interaction was shown, p27/Jab1 binding did not appear to decrease with the reduction of
oxidized thioredoxin. In both MCF-7 breast cancer and LCC2 tamoxifen-resistant breast
cancer cells, reduction of Jab1 levels led to a change in response of the cells to estrogen
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and tamoxifen, respectively. Decreasing Jab1 led to a decrease in cell growth, a
decrease in thioredoxin oxidation, and a decrease in p27 phosphorylation. The role of
Jab1 in tamoxifen resistance has not been explored, and as such these data add to the
current knowledge.

The current study also sought to explore if the effect thioredoxin has on the PTP PTEN
would have downstream effects on the p27 protein. While PTEN is known to be reduced
by thioredoxin, it has not been shown that reducing oxidized thioredoxin through
increasing thioredoxin reductase levels affects phosphorylation of p27 at T157. This
study shows that in both MCF-7 and LCC2 cells, altering the oxidative state of the cell
through thioredoxin reductase can alter the effects on p27 phosphorylated stated. Two
phosphorylation sites were shown to be dephosphorylated after an increase in levels of
thioredoxin reductase. The PTEN/Akt pathway is implicated in this study, but further
studies are recommended, as the time point chosen for experiments may not have been
sufficient to show a strong link.

The major goals of this study were to explore a link between oxidative stress and
tamoxifen resistance, and specifically to look at the thioredoxin/Jab1/p27 pathway as a
target. By identifying the specific data mentioned above, thioredoxin and Jab1 have
been shown to be proteins that may play a role in tamoxifen resistance, and through
further research may be proven to be potent tools for avoiding antiestrogen resistance in
breast cancer.
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Directions for future research
The results of the present study are intended to start a conversation on the role of
thioredoxin reductase, thioredoxin, and Jab1 in antiestrogen resistance. The data show
three areas of possible research.

The reduction of oxidized thioredoxin by thioredoxin reductase showed a significant
reduction in cell growth and p27 phosphorylation in both MCF-7 cells and tamoxifentreated tamoxifen-resistant LCC2 cells. This effect on cancer cells, as well as the
apparent increased sensitivity to tamoxifen, suggest that thioredoxin reductase may be a
potent tool in delaying, reducing, or abrogating tamoxifen resistance. This is not true with
other chemotherapeutics where thioredoxin can interfere with the onslaught of reactive
oxygen species that the chemotherapeutic uses to kill cancer cells. In the case of
antiestrogens that have been shown to create ROS but are not seen to use ROS as the
main pathway of apoptosis, thioredoxin reductase may prove a useful too, and as such
should be explored further in this role.

Jab1 was explored for its role with thioredoxin in counteracting tamoxifen resistance and
estrogen effects in MCF-7 cells. The data show that reducing Jab1 can affect tamoxifen
sensitivity, causing a decrease in cell growth in tamoxifen-treated tamoxifen-resistant
cells. While we were unable to show a change in p27/Jab1 binding in tamoxifen-treated
resistant cells, there was a change in p27 phosphorylation when Jab1 levels were
decreased. There was also an interesting finding of an increase in the reduction of
thioredoxin when Jab1 was decreased. As such, the p27/Jab1/thioredoxin pathway

137

deserves further research to explore other possibilities of interactions between these three
proteins, as the final result is decreased growth in both cancer and tamoxifen-resistant
cancer cells.

The data in this study show a possible role for thioredoxin in affecting the PTEN/Akt/p27
phosphorylation pathway. As thioredoxin is known to interact with other protein
tyrosine phosphatases, these phosphatases should be explored for an effect on
antiestrogen resistance. The PTEN pathway deserves further exploration, as our data
show minimal results. Other pathways may also show other targets for abrogating
antiestrogen resistance.

SUPPLEMENTAL DATA

HuSH 29-mer non-effective (scrambled) pRS vector (Origene) was tested and showed
similar actions to the empty plasmid vector.
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